2007...partnering business opportunities / latin america’s most competitive, peaceful, and stable...

www.hightechchile.com

2007

02 / PARTNERING BUSINESS OPPORTUNITIES

ChileCORFO, the Chilean Economic Development Agency, has been the primary organization within the Chilean Government responsible for promoting economic growth in Chile since 1939.

In 2000, CORFO launched a program designed to attract and facilitate technology-intensive foreign investments. Sponsored by the Ministry of Economy, this program has been operated in coordination with its Foreign Investment Committee. The main objective behind this effort is to position Chile as a biotechnology and service springboard for companies with investment projects that are aimed at Latin America and the world. This program supports the setup of operations for biotechnology and life sciences companies, clinical research initiatives and other high value technology projects including research, development and transfer of emerging technologies.

Over the last 15 years, Chilean entrepreneurs have been researching and developing biotechnology products and services.

Introduction

03

Biotechnology in Chile 2007

PARTNERING BUSINESS OPPORTUNITIES /

As a result Chile is becoming an attractive venue for development and innovation.

CORFO takes pride in introducing the new and exciting opportunities that are available in Chile within the emerging biotechnology and life science sector. This directory will help you become familiar with the Biotech Industry in Chile, its players and also will help you get a better understanding on how the Chilean Government encourages foreign R&D investment and its particular interest in promoting investments targeted at developing the pharmaceutical clinical trials sector.

CORFO invites you to do business with Chilean companies. Besides their highest levels of reliability and competitiveness and their highly skilled labor force, you will also find that Chile offers a very stable and safe environment for your business.


Chile • Chile at a Glance 06

• Why Invest in Chile? 07

• Main International Indexes 07

• Open Economy 09

• Safe Environment 10

• Highly Skilled Workforce 11

Biotech, a National Priority• The Chilean Biotech Industry 15

• Partnership Opportunities 16

• Discover your Chilean Partner 17

• Companies Profiles 19

Clinical Trials Market • Estimated Market Size 79

• Clinical Research Organizations 79

• Companies Profiles 80

Technology Transfer Centers

and Business Incubators• Technology Transfer Centers 96

• Centers Profiles 96

• Business Incubators 107

Incentives for Investors• CORFO’s High Technology Investment Program 116

• How we can help you 117

• Confidentiality 117

• Applying for Financial Incentives 118

• CORFO’s Financial Investment Incentives 119

• CORFO’s Innovation Incentives 120

Contact Us

Contents

05



Chile’s business environment is the result of a policy-driven strategy that has been focused on building sound macroeconomic fundamentals and strong institutions, promoting competition and international integration, and creating a more fair society in which all citizens benefit from economic development. Economic growth has been accompanied by low inflation, a sharp drop in public debt, stable external accounts and strong international reserves. These achievements are the result of Chile’s commitment to economic liberalization and free-market policies, as well as of its pledge to maintain sound and responsible economic management.

Moreover, the country’s modern telecommunications system, its internationally competitive and solid banking sector, high-standard public infrastructure, excellent quality of services and ample availability of qualified workers are key factors that also favorably impress foreign investors.

Source: Foreign Investment Committee (www.foreigninvestment.cl)

Chile

Population: 16.2 million people

Capital City: Santiago

Per Capita Income (PPP): US$11,918

Inflation 2006: 6.2%

Unemployment 2006: 7.4%

Language: Spanish (English learning mandatory)

Currency: Peso

Corporate Tax: 17%

VAT: 19%

Main Exports: Copper, fruit, fishery, forestry products, wine, salmon

Major Trading Partners: USA, Japan, China, Argentina and Europe

Labor force: 6.2 million people

Labor force in Santiago: 2.8 million people (services account for 66.3% of workforce)

Technology clusters: Mining, Aquaculture, Forestry, Agro-industry

Emerging sectors: Human health consortiums and energy located throughout the country

*Sources: Census 2002, National Statistics Institute (www.ine.cl); Ministry of Education (www.mineduc.cl), 2006; Chilean Treasury Department (www.hacienda.cl), 2006; UNESCO 2004.


Chile at a glance

07



Latin America’s most competitive, peaceful, and stable economy

A transparent and low-risk business climate World-class telecommunications infrastructure Outstanding access to Latin American markets Extensive network of Free Trade Agreements with Asia, Latin America, the EU, and the US

Competitive human IT resources An ‘e-ready’ society Exceptional quality of life Competitive business costs Government support

Why Invest in Chile?

The World Economic Forum ranks Chile as Latin America’s most competitive economy. Chile continues to enjoy a favorable business environment position within a selective group of 125 economies worldwide.

Main International Indexes

1st

1st

27th

2006-2007World Competitiveness Index

Among LatinAmerican Countries

Sub-rankingMacroeconimics1st

Overall RankingAmong 117 Countries

Source: World Economic Forum (www.weforum.org), 2006

1st

1st

19th

2005-2009Best Place to do Business

Among LatinAmerican Countries

Among EmergingCountries

Overall RankingAmong 60 Countries

Source: The Economist Intelligent Unit (www.eiu.com), 2005

http://www.weforum.org/

http://www.eiu.com/


Main International Indexes

0 25 50 75 100

1

9

14

20

28

55

70

Iceland - Finland - NZ

Netherlands

Canada

Chile - U.S.A.

Uruguay

Costa Rica

Brazil

Corruption Perceptions Index 2006*(*out of 163 countries)

Source: A.T. Kerney (www.atkearney.com), 2006

India 1

China 2

Malaysia 3

Thailand 4

Brazil 5

Indonesia 6

Chile 7

Philippines 8

Bulgaria 9

Mexico 10

Offshoring(*out of 163 countries)

09



CanadaUSAMexico

A wide network of Free Trade Agreements provide tariff benefits and other incentives helping expand operations into any of the following markets: USA, Canada, Mexico, European Union, Central America, South Korea, the EFTA, Singapore, New Zealand, Brunei, Japan, China, and India. Negotiations will soon be underway to enter agreements with Australia and Malaysia.

Open Economy

VenezuelaColombiaEcuadorPeruBolivia

IndiaChinaJapanSouth Korea

European Union

New ZealandBruneiSingapore

Today, Chile has preferential trade access to the 86% of World’s GDP

- Complement Economic Agreements: Argentina, Brazil, Uruguay, Paraguay, Bolivia, Ecuador and Venezuela.

- Free Trade Agreements: China, USA, Canada, Japan, South Korea, Mexico, Colombia, Panama, Peru, EFTA,

Central America (Costa Rica, El Salvador, Guatemala, Honduras and Nicaragua)

- Partial Scope Agreements: India, Cuba

- Economic Partnership Agreements: EU, P4 (New Zealand, Brunei, Singapore)

- In 2007: Malaysia, Australia, Vietnam and Turkey

PanamaCentral AmericaCuba

BrasilArgentinaUruguayParaguay


Safe Environment

Strong regulatory framework and dominance of the rule of law

New Intellectual Property Law: - The law includes the possibility of patenting microorganisms and genes. - Clinical Trials subject to approval by the National Health Authority. - Biosafety and bioprospecting regulations Currently being developed. - IP in Chile managed by the Intellectual Property Department (www.dpi.cl).

Industrial Property Law No. 19.039 incorporates commitments under the WTO’s TRIPs agreement: - Regulates industrial rights related to innovations - Protection of trade secrets submitted to health agencies

Foreigners protected by: - Universal Copyright Convention - Berne Convention - Rome Convention - Inter-American Copyright Convention

11PARTNERING BUSINESS OPPORTUNITIES /


Foreign investors regularly highlight Chilean human capital as one of the country’s key advantages, emphasizing the high standards achieved by Chile’s universities and business schools.

Chileans are generally recognized as being hard-working, honest and receptive to new ideas, three important attributes that help to make foreign investing straightforward and profitable.

Chile’s high professional standards are reflected in the World Competitiveness Yearbook. The International Institute for Management Development (IMD, Switzerland) in the 2006 edition, ranked Chile 24th worldwide.

Highly Skilled Workforce

The number of Professionals working in biotechnology-related jobs has grown by 17% annually since 1995.

The total number of scientists in Chile has increased 56.9% since 1990.

Academic capacity

Type of Programs Nº of Programs

Undergraduate programs that teach different aspects related to biotechnology 48

Masters programs focused on Biotechnology 17

FhD programs focused on biotechnology 14

Biotechnology and Life Science in Chile 2007Partnering Business Opportunities

BIOT

ECH,

A N

ATIO

NAL

PRIO

RITY

Biot

ech,

a N

atio

nal P

rior

ity

13

Biotech, a National Priority



Chile has taken significant steps to incorporate biotechnology into its economy. Through a powerful range of initiatives, including a new regulatory framework and economic incentives, Chile seeks to develop a world-class biotechnology sector that leverages its global advantage as one of the main producers and exporters of natural resources with high value added products.

Biotechnology development is a strategic priority for Chile. It is expected to contribute to Chile’s economic leadership by helping increase productivity, reduce production costs and increase product quality across a variety of sectors.

Chile, based upon a collaborative private and public joint effort, is committed to creating a desirable location for biotechnology in Latin America. Foreign companies are encouraged to use Chile as a platform for their new developments in biotechnology.

Biotech, a National Priority

BIOT

ECH,

A N

ATIO

NAL

PRIO

RITY

Biot

ech,

a N

atio

nal P

rior

ity


The Chilean Biotech Industry

The biotechnology industry is an emerging and growing sector in Chile. Biotechnology companies increased by 30% the last three years. Most of this activity has been in sectors considered strategic for the country, including agriculture and livestock, human health, fishery, forestry, and industrial biotechnology.

At present, the industry is comprised of 166 biotechnology-related organizations, whose efforts are focused on two main areas: one is to use biotechnology to improve the competitiveness in main export sectors, and the other is to create innovative products for existing and emerging markets.

Category Number of Organizations

Manufacturing Companies 58

Specialized Service Companies 22

University Research Centers 61

Technology Transfer Centers 10

Incubators 15

Total 166

22%

6%

8% 22%

Agriculture and Livestock

Human health and Nutrition

Fishing Industry

Foresty

Industrial Biotechnology

42%



This Government Directory provides information about 58 companies interested in partnering with other entrepreneurs, governments and universities around the world.

Highly skilled professionals have developed innovative products and services, and these companies are a valuable alternative to increase your global presence and make your R&D activities more cost-effective.

Companies represented range from human health to industrial biotechnology in fields such as aquaculture, forestry, agriculture and livestock, and mining, where Chile is a worldwide leader.

Partnership Opportunities

Health, Medical, Diagnostics 16

Food Biotechnology, Nutrition Science 2

Aquaculture, Coastal and Marine Biotech 4

Agricultural, Environmental Biotechnology - Biofuels,

Biofertilizers, Bioremediation, Geomicrobiology22

Arid Zone and Desert Biotechnology 1

Patents, Publications, Inventions, IPRs 3

Gene-based Bioindustries 1

Bioinformatics, Nanobiotechnology 1

Classical Fermentation and Bioprocess Technology 0

Others 8

Source: Validation Study of Chilean Biotechnology CORFO, January 2007

Biotechnology Categories Number of Companies

BIOT

ECH,

A N

ATIO

NAL

PRIO

RITY

Biot

ech,

a N

atio

nal P

rior

ity


Discover your Chilean Partner

Adexus S.A.

Agrobiotec S.A

Altalena S.A.

Anprog A.G.

Apablaza y Santalices Ltda.

Astax S.A.

Austral Biotech S.A.

Avance Biotecnologies, Chile Ltda.

Bioagro S.A.

BioAlgae S.A.

Biodinámica S.A.

BioEnlaces Ltda.

BioEquity S. A.

Biogram S.A.

Biohídrica, Biotecnologías del Agua Ltda.

Bioingemar Ltda.

Bio Insumos Nativa Ltda.

BioPlanet Ltda.

Bioscan S.A.

BiosChile Ingeniería Genética S.A.

BioSigma S.A.

Biosonda Corporation

Biotecnologías Antofagasta Ltda.

Biotecnológicas S.A.

Biotecnor Ltda.

Bio Tritón S.A.

C.G.M. Nuclear S.A.

Clarke Modet & Co.

Colmenares Santa Inés S.A.



Criadero Nueva Suiza Ltda.

Diagnotec S.A.

Ecoforce S.A.

Eco Tecnos S.A.

Eugenio Marín S.A.

Flores y Acevedo Abogados y Consultores Ltda.

Fumigaciones y Exportaciones Ltda.

Fundación Biociencia

Fundación Chile

Fundación Ciencia para la Vida

Genética y Tecnología Ltda.

GenFor S.A.

Industrias Grasas y Aceites Ltda.

Laboratorio Centrovet Ltda.

Laboratorio Linsan S.A.

Laboratorio Veterquímica

Lucien Biotechnologies

Mygoldex Chile Ltda.

NEOS, Servicios de Gestión Tecnología Ltda.

Oncoblomed

Patagonia Neuroactive Biotechnology

Plataforma360 Consultores Ltda.

Quitoquímica Ltda.

Sociedad Punta del Cobre S.A.

Schaffeld Kriman & Villegas Ltda.

Tauern S.A.

Internacional Trade Consultants S.A.

Valtek Diagnostics

Voz Chile Ltda.

BIOT

ECH,

A N

ATIO

NAL

PRIO

RITY

Biot

ech,

a N

atio

nal P

rior

ity


Adexus S.A.

Ownership and StructureRegistration NumberLegal RepresentativePostal Address

Private Business Partnership96.580.060-3Carlos Busso VyhmeisterMiraflores 383, 20th Floor, Santiago

Primary ContactJob TitlePhone NumberFax NumberMobile NumberEmail Address

Carlos Busso VyhmeisterPresident and CEO(56-2) 686 1000(56-2) 686 1201--

When Established 1990

N°of Employees 349PhD 2Master degree 6Bachelor Degree 200

Organization Description

ADEXUS is the leading solutions integration company that serves Chile, Peru, and Ecuador. Since 1990, ADEXUS has provided open solutions and specialized services in the information and communication technology fields. The company represents more than 40 brands and leading international technology companies, providing design and implementation of multi-platform solutions across the country in a wide variety of fields, including finance, telecommunications, government, higher education, industry, commerce and services, among others. ADEXUS’ mission is rooted in the use of technology to streamline its clients businesses through the creation of technological solutions and innovative services to enable the transformation and integration of business processes and to development new business models.ADEXUS has formed a support area with the knowledge to assist high end computing as clusters for R&D used in biotechnology, chemistry and mathematics.The understanding of the client’s needs allows ADEXUS to apply its creativity, integration capacities and experience with flexible and specific IT solutions.

Websitewww.adexus.cl

Business Areas

Products/Services and Operation

ADEXUS experience in these areas makes it the major provider of computer platforms and support for biotechnology in the region:Hewlett Packard High Performance Technical Computer: runs applications for biotechnology (e.g. Gaussian and NAMD), chemistry and mathematics.Support: a trained staff, which implements and maintains the solutions.Housing and Hosting: ADEXUS data center provides customers with a highly secure environment for sensitive and confidential information.



Agrobiotec S.A.


Private Company77.294.200-5Gerald Edgard Wells HoneymanOngolmo 272, Concepción, Chile


Gerald WellsDirectory President(56-41) 124 6049(56-41) 790 0500(56-8) 228 [email protected]


N°of Employees 10PhD 2Technicians 7Administrative 1


Agrobiotec S.A. is a private company, with a corporate team of three directors and two managers. The company has two main areas: Plant Propagation and Research & Development.In the plant propagation area, the company is focused on the production of different varieties of Zantedeschia, mainly royalty varieties. In the first year the company produced 250,000 TC for different customers. Part of the production was sold to Green Harvest Export (NZ). The main goal for the next three years is to produce over two million plants in- vitro, mainly ornamental and other species such as blueberry, leucocoryne, gentiana and others.The Research & Development area is mainly focused on obtaining grants for research and development of other species with a focus on nutrition, medicine and ornamental purposes. Agrobiotec is working to introduce new protocols in plant propagation and develop new methods in plant production with lower costs and premium product quality.

Website-

Business Areas


Agrobiotec S.A. offers services in plant micropropagation in different species, mainly in ornamental plants: zantedeschia, leucocoryne, gentiana, and in fruit trees and forest trees.The products produced by the company have plant breeder rights; they are exclusive varieties in plant micropropagation, specifically in zantedeschia and gentiana.The main advantage is that Crop and Food (NZ) certify our products as virus-free. Agrobiotec S.A. has annual production agreements with international customers because of the premium quality of the products. The company can produce plants in the opposite season of some parts of world and supply customers for special occasions.Agrobiotec mainly uses micropropagation, and in the future will use immersion systems in its plants to increase our production level.Agrobiotec currently has a lab with a capacity of 750,000 plants with plans to have a new lab with 1,200,000 million plants capacity within the next eight months. This will enable us to guarantee our customers the desired production volume. We will have 18 flood cameras, 3 media sterilizers, and rooms necessary for production.Social responsibility is one of the company’s goals. It has hired seven people from the location area and plans to hire up to 30 people working in the biotechnology lab, with the necessary training by the company staff.Agrobiotec needs equipment to work on other techniques such as somatic embryogenesis, somatic hybrization, molecular marker, virus detection and varietal identification by molecular techniques.

BIOT

ECH,

A N

ATIO

NAL

PRIO

RITY

Biot

ech,

a N

atio

nal P

rior

ity


Altalena S.A.


Private Company76.593.380-3Roni A. Gloger7530193


Roni A. GlogerManaging Director(56-2) 204 4550(56-2) 204 8711(56-9) 8294 [email protected]


N°of Employees 7PhD 1Bachelor 2Technicians 4


Altalena Biotechnologies is a private owned biotech company. The main goal of the company is to generate products and services to satisfy the needs for some of the key industrial areas in the Chilean economy, such as agriculture, forestry and foods.The company business model is intensive in the use of open innovative sources, acting as a commercial platform to give biotech solutions to its clients utilizing Chile’s comparative advantages, such as economic stability, climate, geographic position and regulations.Altalena has currently two main business areas: Plant propagation and R&D services.

Websitewww.altalena.cl

Business Areas


ProductsAltalena Biotechnologies offers micropropagation for different species of plants, mainly fruit and ornamental. With the support of public funds the company is developing the Temporary Immersion Bioreactors technology to attain more efficient micropropagation rates. Altalena Biotechnologies is also working permanently in the development of new protocols for species with commercial interest.The company is in the first stages of the implementation of additional related techniques such as virus detection, molecular markers and varietal identification by molecular techniques.

ServicesAltalena Biotechnologies offers customized solutions using biotech tools in agricultural, forestry and food industries, based on both the country and the company’s business model comparative advantages.



Anpros A.G.


Industrial Association82.266.900-KJaime Ibieta SotomayorNueva Los Leones 07, 13th Floor, Providencia, Santiago


Mario SchindlerGeneral Manager(56-2) 335 3686(56-2) 335 3685(56-9) 159 [email protected]


N°of Employees 6PhD Master Degree 1Bachelor Degree 3


The National Association of Seed Producers (ANPROS) is an industrial organization of producers, distributors, marketers, investigators and other organizations that sympathize with the achievement of the agroindustrial sector. It was founded in Santiago, in December of 1959 by a group of farmers that were members of the Ministry of Agriculture’s Certified Seed Registry Office.

Business Areas


The objectives of ANPROS are:- To strengthen bonds between its associates;- To maintain relationships with analogue institutions of other countries;- To study and implement the procedures destined to improving production, commerce and prestige of

the seed industry;- To study and coordinate the measures destined to prevent and fight fraud, forgery and adulteration

of seeds;- To maintain the relationships needed with other national and international Associations, Federations

and Confederations and even belonging to these institutions, with the objective of achieving common interest goals that its associates require;

- To represent the interests of its associates to the public authority, especially the Ministry of Agriculture and SAG (Agricultural and Livestock Service), and to sponsor every measure that allows these associates to better achieve these objectives and support the progress of Chile.

Websitewww.anpros.cl

BIOT

ECH,

A N

ATIO

NAL

PRIO

RITY

Biot

ech,

a N

atio

nal P

rior

ity


Apablaza y Santelices Ltda.


Private Organization78.376.890-9Nibaldo Apablaza ReyesRojas Magallanes 126, La Florida, Santiago


Mónica Santalices ArufeR&D Manager(56-2) 281 3019(56-2) 493 5583(56-9) 231 [email protected]; [email protected]


N°of Employees 5PhD 3Technicians 1Administrative 1


A&S a laboratory, in which the main strategy and research activities are:- Analytical and diagnostic area.- R&D area: Particularly biotechnology, bioprocess, microbiology, secondary metabolites, and in-vitro

cultures.- Registration area: Patents and registers.Since 1993, it has worked with and for productive companies, looking for business opportunities and real solutions to production problems. A staff of experienced scientists and technicians runs the laboratory.

Websitewww.ayslab.cl

Business Areas


A&S Lab provides analytical and diagnostic services (agriculture and animal) especially for diseases (viruses, fungi and bacteria), animal food (physicochemical, biochemical, microbiological analysis), soil, tissues (nutritional, chemical and biochemical analysis) and others. It uses techniques such as: ELISA, immunoblots, chromatography, PCR, indicators plants, electrophoresis, microscopy and analytical techniques. Its R&D services focuses mainly in biotechnology, bioprocess, microbiology, and secondary metabolites, in- vitro cultures.The Services registration area covers patents and registers in alliance with a legal firm.



Astax S.A


Private Partnership78.658.200-8Jorge Pérez Pérez12 de Febrero 1531, Iquique, Chile


Jorge Pérez PérezGeneral Manager(56-57) 511 284(56-57) 331 [email protected]


N°of Employees 15PhD 1Bachelor Degree 2


ASTAX is a company sponsored by PANADES which in the last ten years has developed a research line, focused on the cultivation of the Haematococcus pluvialis microalgae. This algae contains about 2 to 3% of Astaxanthin, a natural pigment largely demanded in the salmon and trout production. Research results allow the company to rely on an innovating cultivation technology of the microalgae and the natural Astaxanthin extraction process from it, feasible to apply in an industrial production level.The technology considered in the process developed by ASTAX, presents several competitive advantages compared with productions in other places worldwide. In fact, the high photonic radiation available in the northern part of Chile provides the microalgae a growing environment, which results in less production costs and in a low investment level related to the incomes and the expected profit. Also the high purity of the desert atmosphere contributes to avoid classical microbial contamination of the algae tissue.

Websitewww.astax.cl

Business Areas


Core products and/or services that ASTAX offers:Natural astaxanthin, FDA approved as feed and food grades. Astaxanthin produced by Haematococcus algae contains 20% more of other complimentary carotenoids then other natural sources. As a natural product it is by far the most accepted by consumers than the sythetic ones. Additionally, it contains some essential fatty acids.The main advantage is the natural organic origin. The salmon industry worldwide has been using mostly Synthetic Astaxanthin, due to the natural pigment high production cost obtained from the algae. But based on the accomplished studies and the technological advances, costs and sale prices have reached a balance and today practically are at the same level, which obviously suppors the natural industry due to the client’s preference for this option over the synthetic Astaxanthin.Current operation includes a pilot plant producing 2 kg/month of pure astaxanthin.

BIOT

ECH,

A N

ATIO

NAL

PRIO

RITY

Biot

ech,

a N

atio

nal P

rior

ity


Austral Biotech S.A


Private Corporation96.549.170-8Carlos Busso VyhmeisterSan Sebastián 2952, 5th Floor, Las Condes, Santiago


Virginia Garretón Rodríguez.CEO(56-2) 333 3519(56-2) 207 6647(56-8) 479 [email protected]

When Established 2005 N°of Employees 10PhD 2Bachelor Degree 2Technical Support 1Secretary 1


Austral Biotech was established in 2005, created with private equity capitals. The company’s goal is to invest in relevant biotechnological products developed in Chile. Austral is focused on the development of quick methods to detect or clean compounds with an important impact in the production processes of all kind of industries. Using public genomic information and research, the company is building databases of small proteins (BioMagnets), which can specifically bind to other molecules. These small molecules will be modified to optimize features like: stability, specificity, adaptability to detection methods, etc. BioMagnets will be used to develop biosensors and field detection kits (e.g. agriculture and aquaculture) and create biofilters for industries such as the wine industry. It is also interested in investing in selected biotechnological projects developed by other organizations.

Websitewww.australbiotech.cl

Business Areas


Austral Biotech S.A. plans to produce detection kits for quality control analysis, and biofilters or chemical preparations to selectively bind to or remove unwanted compounds from all kind of products (wine, food preparations, waste residues, etc). These products are to be developed in collaboration with the industries that require them, assuring that the products really account for the consumers’ needs. Also the creation process of kits will be standardized to obtain them in a very short time.The company’s products will be developed to meet specific needs required by customers, and will be designed for direct use in the field without any laboratory instrument or highly qualified human intervention.



Avance Biotecnologies, Chile Ltda


Private Corporation77.601.120-7Jorge Tchimino DujovneBarón de Juras Reales 5382, Conchalí, Santiago


Juan M. RencoretSales Manager(56-2) 623 3266(56-2) 623 0638 (56-9) 230 [email protected]




Avance Biotechnologies began its operations in May 2001 as a privately owned company dedicated to research, development, production and sale of biotechnological products geared towards agricultural and forestry industries in local and foreign markets. The company property belongs to four partners. The partners are: two researchers, one businessman and one multinational company sales executive in equal partnership. The company has a 9,000 sq ft facility located in Santiago Chile. It is a pioneer in next generation pesticides products for the agricultural and forestry industries. The company has a research laboratory dedicated to the development of new products and technologies with 5 fully assigned and highly skilled professionals, in addition to agreements with experts in different development areas. Our production facility is designed to exceed over 35% of sales needs. The main achievements are: five products commercially available, 15 new developments (five of them completely developed), two patent applications, over US$ 2.5 million in sales, more than 50 tons of products shipped and approximately US$ 1 million invested in R&D.It has distribution agreements with three of the five main distributors in the country. Product samples have already been delivered to five countries. The company is working on obtaining the ISO 9000 certification. The company has written more than 70 highly advanced technical documents that have been delivered to customers, three oral presentations in congresses (two of them international) and one third party publication discussing our achievements.

Websitewww.avancebiotechnologies.com

Business Areas


Avance Biotechnologies’ main products are: - 3TAC wide spectrum biofungicide for preventive and curative purposes, innocuous and certified for use in

organic agriculture by BCS-Germany. - A5, bioinsecticide for thrips control, innocuous and certified for use in organic production by BCS-Germany. - 3TACIbeta, biobactericide to control bacterial diseases in trees and plants. - BIOTENS, organic surfactant for application of organic and chemical products, certified for organic production

by BCS-Germany. - 3TAEX, pruning paint that includes our wide spectrum biofungicide.The company provides environmentally safe project development services for the agricultural industry. The company’s competitive advantage is to allow customers to incorporate new technologies without changing the farming routines. Its production techniques are highly advanced and allow production workers to use the products using standard production procedures. The company is implementing the ISO 9000 standard. Its laboratory provides a production line with highly stabilized supplies. Avance Biotechnologies internally produces most of its products, except 3TAEX, which is produced by an external supplier. Its current annual billing rate is US$ 1 million.The production facility has 7,000 sq ft. The production capacity is 75 tons / year and is being utilized at 60%. The business’ main suppliers are related to product packing. Its basic needs are related to access to highly sophisticated laboratory equipment required for our investigation. Currently, it rents the equipment used in their laboratories.

BIOT

ECH,

A N

ATIO

NAL

PRIO

RITY

Biot

ech,

a N

atio

nal P

rior

ity


Bioagro S.A.


Private and Registered Company96.576.210-8Paul Abogabir SMaría Auxiliadora 721, San Miguel, Santiago


Paul Abogabir SGeneral Manager(56-2) 512 4007(56-2) 552 8931(56-9) 275 [email protected]




BioAgro S.A. is a Chilean biotechnology company that has dedicated the last 15 years to developing a family of phytosanitary products for agriculture named Biorend.Biorend is a natural organic, biodegradable, non-toxic and non-polluting product. Its active ingredient is a natural polymer derived from the Chitin, called Chitosan, which is produced from the shells of King Crab and Snow Crab captured by fishing companies in the Strait of Magellan, XII Region of Chile. Biorend is manufactured exclusively for Bioagro by Biotex S.A. in its industrial plant located in the XII Region of Chile. Biorend has been certified by the Swiss company, IMO, for its use in Organic Agriculture under Regulation (EEC) Nº 2092/91 and USDA, AMS 7 CFR Part 205, National Organic Program, Final Rule. BioAgro and Biotex and its related companies have developed several patent inventions to protect intellectual property in areas such us agriculture, biological agriculture and food industry.

Website-

Business Areas


BioAgro produces biological products for the control of insects and pests. It also processes a unique raw material (Chitin). The company offers agriculture producers integral consulting and advisory in matters of sustainable agriculture, use of organic and biological products and good exploitation techniques training.It has technology transfer contracts through the Invention Patent Method named: A Method for the Recuperation of Decayed Agricultural Plantations.



BioAlgae S.A


Private Corporation76.595.290-5Felipe Andrés Elso TinocoLientur 559, Concepción, Chile


Felipe ElsoGeneral Manager(56-41) 220 7119(56-41) 220 [email protected]




BIOALGAE S.A. is a private company created in 2006. It attends the needs of the feed/food industry for animals and humans, cosmetics and pharmaceutical in the chemistry field.The company’s mission is to provide bio-molecules derived from micro algae for the animal and human markets.BIOALGAE specializes in the search of bio-molecules and the elaboration and marketing of products based on phycoactives extracted from its own micro algal cultures.

Websitewww.bioalgae.cl

Business Areas


BIOALGAE produces a standardized colorant additive for salmon feed based on natural astaxanthin. The colorant will be available in different concentrations and formulations.This product has been developed to comply with the technical requirements of the food plants and the effective norms in Chile, USA and EU.

BIOT

ECH,

A N

ATIO

NAL

PRIO

RITY

Biot

ech,

a N

atio

nal P

rior

ity


Biodinámica S.A.


Private Company96.955.070-9Claudia López-LaportAvenida Sucre 923, Ñuñoa, Santiago


Claudia López LaportGeneral Manager(56-2) 269 6421 - (56-2) 269 6427(56-2) 269 6427 - (56-2) 341 9781(56-9) 299 [email protected]


N°of Employees 10Master Degree 2Bachelor Degree 5


Biodinamica S.A. is a private company, founded in 2001 by an outstanding group of Chilean businessmen and scientists. Since the beginning, it has been committed to biotechnological product development for the aquaculture market. The company has already obtained several recognitions. In 2005 Biodinamica obtained a Certification from SGS Chile Ltda. for its line of Biotechnological Products, according to the Chilean Standards 2769 NCh and NCh 2770 (INN). During the same year, the Agriculture and Livestock Service granted Biodinamica the sanitary register for the first immunostimulant for salmons registered in the country, which allows its commercialization and export. Besides commercial activities the company has a strong focus on R&D, particularly in fish immunology, production of bioactive substances from natural sources, food additives, etc., which is supported by a consultant and joint projects of universities and institutions in Chile and other countries (Spain, USA, Mexico, Venezuela, Colombia). The company is founding partner of ASEMBIO, Chilean Association of Biotech Industries.

Websitewww.biodinamica.cl

Business Areas


Its main biotechnological product is Interac® 100; an injectable immunostimulant obtained from natural sources, which is prescribed to improve natural defenses, sanitary conditions and prevent diseases. The product is used in salmon farms to prevent SRS (Salmon Rickettsial Disease), the main salmon disease in Chilean aquaculture and other important diseases, which produce estimated losses over US$ 100 million each year. Currently, the main sanitary tools used to control this disease are based on curative therapies (antibiotics) proper management (lowering densities, reducing stress, etc.) and vaccines. The inherent risk behind the use of antibiotics for long periods is the environment damage and bacterial resistance generation, which could lead to the inefficacy of such treatments and negatively affect the aquatic environment.Biodinamica S.A. foresees that the massive use of antibiotics in animal health may be a major commercial entry barrier limiting the markets where the product is going to be targeted. Additionally, the “antibiotic resistance transfer” from one bacterium to another and the eventual transfer of such resistance to pathogens, which might affect humans, is a crucial risk. Antibiotics are known to be ineffective against viral diseases, which are important diseases without treatment tools available. We have other products in different phases of development.In the future the company would need support in: a) R&D in fish immunology for better understanding the mechanism involved in the immune response to

fish pathogens.b) Support for the incorporation of products like coadjuvants of vaccines for animal health. c) Extending the use to other fish species and other markets.d) Extending the number of bioactives from Chilean natural sources, so better extraction methods are

required.



BioEnlaces Ltda.


Private Company77.533.350-2Juan Carlos VeraLos Aruacanos 2202, Providencia 756-0688


Juan Carlos VeraCEO(56-2) 325 2983(56-2) 580 0167(56-9) 840 2894 [email protected]


N°of Employees 6PhD 2Master Degree 1Bachelor Degree 3


BioEnlaces was founded in 2000 with the mission to foster the responsible use of biotechnology in Chile. The organization seeks to achieve a connection between researchers, businessmen, public policies producers and the people to establish an integrated national system to develop biotechnology, which addresses Chile’s interests and needs. BioEnlaces is a consulting firm with leading expertise in the emerging field of biotechnology; it is formed by professionals who provide their specific knowledge to the common vision of biotechnology as an instrument of Chilean development. BioEnlaces is an entity that relies on the strengths and capacities required for the execution of any study or advising, and stand as a dedicated company for biotechnology transfer in areas of strategic advice, scientific consultation, communication and marketing management. BioEnlaces has worked to produce national and international contact networks, and our participation in the last five BIO (Biotechnology Industry Organization) international conferences has strengthened these networks.

Websitewww.bioenlaces.com

Business Areas


BioEnlaces understands that a successful project requires expertise, technical resources, and the organizational commitment to complete all necessary tasks in a timely manner with the highest level of technical, professional, and scientific involvement. BioEnlaces provides consultancies, evaluations and studies about biotechnology applied to education, government management and communication and knowledge management. Some of the studies made during the last year were:- “Cattle Agricultural and Forest Biotechnology: An Opportunity for Sector Development”, destined to promote

biotechnology among businessmen of the agricultural, forest, cattle and wine sectors. Project financed jointly by the Foundation for the Agrarian Innovation (FIA).

- Production of Biosafety website contents for the National Environment Commission (CONAMA), as part of the project “Development of a Biosafety National Frame for Chile”

- CD-ROM “Understanding the Agro-biotechnology”. Project financed jointly by the Foundation for Agrarian Innovation (FIA).

- Project “BioEducation”; interactive tools to teach Biotechnology in High Schools. Financed jointly by a State Institution National Technology Fund (FONTEC)- Economic Development Agency (CORFO).

- Consultancy study “Evaluation of Capacities and Institutional Needs of Public Institutions Involved and Associated with the Biosafety Law and the Protocol of Cartagena” requested by the Government of Chile as part of the program of “Development of a Biosafety National Frame for Chile”, financed by GEF, administered in Chile by PNUD through CONAMA (National Environment Commission).

BioEnlaces is the first company of its kind in Chile and it has experience on consultancy studies for the government being the only organization on the biotechnology sector qualified as a consulting firm by the Congress of Chile.BioEnlaces also has experience as a consulting firm with official international organizations such as the United Nations

BIOT

ECH,

A N

ATIO

NAL

PRIO

RITY

Biot

ech,

a N

atio

nal P

rior

ity


BioEquity S.A.


Private Corporation76.379.170-KJosé Manuel ContrerasOngolmo 272, Concepción, Chile


José Manuel Contreras, Dr Mike Carson.CEO(56-41) 740 202(56-41) 790 500(56-9) 519 [email protected]



Organization DescriptionBioEquity is in the business of applying advanced forestry genetics, tree breeding and biotechnology to add value to forest plantations by:- Developing, testing and commercializing improved genetic material of pines and eucalyptus in the form of seed, cloned material and

plants - Supplying forestry genetics, molecular biology and other biotechnology solutions, products and services to the Chilean and South

American plantation forestry marketBioEquity has three main areas of operation: - Products & Marketing: producing and marketing advanced forestry varieties of pines and eucalyptus. - Services & Technology: providing business solutions and technologies in the form of consulting and advisory work, contract research &

development (R&D), and delivery of technical know-how and patented products and systems. - Administration and Management: under contract BioEquity manages and operates the tree breeding resources of strategic partners

as a separate profit center, including seed harvesting areas, seed orchards, tree breeding programs, provenance and clonal trials, micropropagation laboratories, and tree nurseries.

For access to technical resources, BioEquity relies on the strategic relationship with its founding partners Carson Associates Ltd. of New Zealand, Gryphon Resources of Canada and Agromen of Chile. The company also has additional strategic alliances with R&D organizations and scientific institutions in New Zealand, Australia, Canada, USA and Europe to supplement its in-house resources.

Websitewww.agromen.cl

Business Areas


BioEquity’s core products and services include:(a) Highly improved plantation forestry varieties of pines and eucalyptus in the form of seed, microcuttings, mother plants and

seedlings for reforestation.(b) Business solutions and technologies in the form of consulting and advisory work, contract research & development (R&D),

and delivery of technical know-how and patented products and systems.(c) Operating the tree breeding resources of strategic partners as separate profit centers, including seed harvesting areas, seed

orchards, tree breeding programs, provenance and clonal trials, micropropagation laboratories, and tree nurseries.BioEquity’s products and services differ from the competition by its large value-added, low-cost and timely delivery to end-users. The innovative nature, custom design and proven quality of the company’s flagship technologies can significantly increase the customer operating margins, including specific end product quality and delivery characteristics.BioEquity relies heavily on the use of superior technologies and systems required in advanced tree breeding; molecular biology; tissue culture and clonal replication (including somatic embryogenesis, tissue culture and other micro and macropropagation systems); clonal tests and data analysis; advanced greenhouse management; and tree nursery operation with limited risk exposure.The main competitive advantage of BioEquity supply is a staged, tested and early deployment of technologies and genetic gain. Products and services can be custom-designed and delivered to meet the client’s special needs. The company utilizes inputs ranging from elite forestry germplasm to tissue culture laboratories to tree nurseries along its production chain. As a result, BioEquity employs: - Elite seed and microcuttings - Containerized greenhouses- Seed orchards & control-pollinated crosses - DNA fingerprinting for quality control- Seed orchard management & production - Bareroot and containerized transportation- Provenance, family and clonal trials - Genomic & molecular marker databases- Genetic data management, storage and analysis - DNA sequencing and micro-array facilities- Tissue culture labs & cool storage - Genetic transformation labs- Somatic embryogenesis and cryostorage - Insect and disease resistance screening



Biogram S.A


Private Organization99.558.330-5Jaime Quiroz GarcíaLos Canteros 8534, La Reina, Santiago


Pedro Miranda.Commercial Manager(56-2) 275 4589(56-2) 275 4588(56-9) 319 [email protected]


N°of Employees 20Master Degree 1Bachelor Degree 8Technicians Operators 5


BIOGRAM is a company oriented to the development, production and sale of biotechnological supplies for agriculture production. The company was created in 2004 although BIOGRAM’s owners and professionals combine for almost 20 years of relevant expertise in the area. BIOGRAM has created several new products that are already in the market and has improved other from previous experience.BIOGRAM’s facilities are located in an industrial area in Santiago and include: an industrial plant for liquid extraction, organic materials formulation, and powder products mixing and packing; laboratories for microbiological product production; a laboratory for product research and development and quality control; in- vitro plant propagation area; greenhouses; industrial services areas; offices; and administrative and commercial services areas.

Websitewww.biogram.cl

Business Areas


BIOGRAM’s main products are:- Biostimulants, obtained from microbiological, marine and vegetal sources.- Biofertilizers, such as products based on micorrhizal fungi inoculants and rhizobium bacteria inoculants- Biopesticides, such as agrobacterium radiobacter and trichoderma harzianum based products, biocontrolers

of bacteria and fungi that produce plant diseases.- In- vitro plant micropropagation.The main BIOGRAM production processes are:a) Fermentation and formulation of different microorganisms to obtain products for specific applications as

biocontrolers, PGPR, fertilizers, etc.,b) Extraction of active agents from vegetal sources, andc) In- vitro plant propagation.The company’s full capacity production it’s 4,000 liters/day. Microbiological products capacity ranges between 100 and 1,000 units/day, depending on the volume or weight of the final packaging size. In order to increase its product line, BIOGRAM is looking for companies or individuals that produce and / or sell biological or natural products for agriculture that have been proven and approved at field scale. The company hopes to find these products to produce in Chile by means of a know-how transfer agreement.The Chilean market for these products should be very interesting because of the production volume, which includes fruits such as grapes, avocado, peaches, apples and others; all of them destined to export, as well as berries, mainly blueberries, raspberries and strawberries. Tomatoes are also interesting, especially as tomato paste for export.Efficient products based in microorganisms such as biocontrolers, plant growth promoting m.o., and biofertilizers should have a high demand in Chile.

BIOT

ECH,

A N

ATIO

NAL

PRIO

RITY

Biot

ech,

a N

atio

nal P

rior

ity


Biohídrica, Biotecnologías del agua Ltda.


Private, Limited Company78.365.180-7Pabla Viedma and Davor CotorasAníbal Aracena 571, Ñuñoa, Santiago


Pabla Viedma and Davor CotorasVice-President and President(56-2) 239 3822(56-2) 239 [email protected]


N°of Employees 2PhD 1Master Degree 1


BIOHIDRICA® is a private company dedicated to research and technological innovation, services and products commercialization in microbiology and environmental engineering. Its main business areas are:- Environmental Biotechnology - Bioleaching and Biomining- Food Microbiology- Industrial Property BIOHIDRICA® is a company of research and development, providing consultancy services and product sales for the detection and control of environmental contamination. It is committed to providing a customized service to the client.BIOHIDRICA® provides environmental biotechnology services in the following areas:

Websitewww.biohidrica.cl

Business Areas


• Ecotoxicology • Toxicity bioassays • Bioremediation of water

Bioleaching and biomining services related to: • Specialized analyses in biohydrometallurgy • Preliminary evaluation of bioleaching capacity • Tests of bacterial leaching

Food microbiology: • Microbiological consultancy office • Microbiological food quality testing • Mobile laboratory - MoviLab®

Services in industrial property: • Identification of invention patentability• Preparation and drafting of invention patents • Consultancy office on industrial property

The company produces the following products: •Toxicity bioassay kits • Acid drainages of mine control systems



Bioingemar Ltda.


Business Partnership77.328.470-9Viana Beratto VillagraAvenida Collao 1691, Concepción, Chile


Viana BerattoResearch and Development Director(56-41) 316 138(56-41) 321 169(56-9) 888 [email protected]




Bioingemar Ltda. is a small family business established in 1999. Bioingemar has developed a natural pigment that complies with the quality requirements of the United States and European markets. Bioingemar has obtained an exclusive sales contract with one of the largest companies in the area of pigments and dyes.In January 2000, Bioingemar began to export the products to its distributor in the USA, who sold the products in the North American and European markets. After this, Bioingemar confirmed its capacity to develop new products that are commercially competitive worldwide.

Website-

Business Areas


Bioingemar is specialized in the use of raw materials from the sea, with a particular focus on the pharmaceutical and cosmetic industries. Its products include algae pigments for biological marking; guanine and antioxidant extracts for cosmetic use, oils, etc.Bioingemar also provides research and development services in the chemical and biochemical areas.

BIOT

ECH,

A N

ATIO

NAL

PRIO

RITY

Biot

ech,

a N

atio

nal P

rior

ity


Bio Insumos Nativa Ltda.


Private, Limited77.807.250-5Ximena Astorquiza, Eduardo Donoso, Pabla RebolledoCasilla 16 D, San Javier, Chile


María Alejandra Vargas ContrerasCommercial Manager(56-73) 324 306(56-73) 324 306(56-9) 239 [email protected] [email protected]


N°of Employees 14PhD 3Master Degree 1Bachelor Degree 1Operators 5


Bio Insumos Nativa Ltda. is located in the VII Region and is dedicated to resolving farmer’s problems. The company’s purpose is to make a Natural Biological Control in Agriculture. It is committed to protecting the environment and teaching farmers how to produce in a healthy way. Bio Insumos Nativa is constantly investigating and developing new products that can meet strict quality controls

Websitewww.bionativa.cl

Business Areas


The company’s products are different from the competition in relation to prices, R&D processes and technical support. These products are mainly insecticides, pesticides, bactericides, and fungicides. Its manufacturing facilities are located in a production plant of 100 meters squared. Bio Insumo Nativa’s main product is Trichonativa®. This is a biotechnological product based on Trichodermas from various National Parks, which shows an excellent response to control several fungi of phytopathological importance, such as Phythophtora, Cladosporium, Rhizoctonia, Sclerotinia, Botrytis, Alternaria, Fusarium y Venturia, among others. It is made with highly active strains, which have a higher aggressiveness and adaptation capacity to local conditions, protecting the biodiversity and environment at the same time. The Foundation of Agrarian Innovation (FIA) acknowledged those characteristics and the success of the company’s efforts with the Award for Agricultural Innovation 2003.



Bio Planet Ltda.


Private77.332.320-8Jorge GaticaZañartu 1482, Office B-216, Santiago


Jorge GaticaDirector(56-2) 237 9593(56-2) 237 [email protected]




Bioplanet Ltda. has been building a network of relationships between key players in the Chilean biotechnology industry, including businessmen, researchers and public authorities.Bioplanet is a bimonthly magazine which is distributed between opinion leaders and decision makers using strong alliances with trade organizations and MBA programs of prestigious institutions.The company has an internet portal which receives around 20,000 visitors per month.Last but not least, Bioplanet has been linking interesting biotech and biopharma entrepreneurs and/or businessmen with angel and venture capitalist. Since 2003, Bioplanet has catalyzed investments for more than US$ 5 Million.

Websitewww.bioplanet.net

Business Areas


The company’s services include business networking and market analysis. Bioplanet is focused on building a massive and strong network connecting biotechnology markets.

BIOT

ECH,

A N

ATIO

NAL

PRIO

RITY

Biot

ech,

a N

atio

nal P

rior

ity


Bioscan S.A.


Private/Business Partnership 96.729.480Roberto ValladaresDr. Carlos Charlin 1486, Providencia, Santiago


Roberto ValladaresCEO(56-2) 374 0884(56-2) 374 0887(56-8) 409 [email protected]


N°of Employees 15PhD 1Master Degree 3Bachelor Degree 9Other 2


BIOSCAN is a biotechnology company with two areas of specialty: Molecular Diagnostics and Clinical Trials, and Seaweed small molecules application. Since 1994, BIOSCAN has developed PCR (Polymerase Chain Reaction) detection for 50 human pathogens related to gynecological and periodontal diseases. The company is the largest supplier of this kind of service in Chile. In 2004 the company hired a new management team and became the first Chilean biotechnological company to join science skills and management to develop new projects with strong market orientation. Today BIOSCAN is successfully participating in Surver’s CAP. BIOSCAN’s continuous improvement has resulted in close relationships with research centers, clinics and hospitals in Chile and earned a good recognition among specialists.Recently the company began to market its services to use PCR to detect 23 viruses in grapes, pip fruits and stone fruits. These tests are necessary to achieve certification from the Chilean Agricultural Sanitary Authority. Also, it has patented a biopesticide with antiviral effect in plants (a polysaccharide extracted from a Chilean red seaweed), and continues to research for new applications of this product. Additionally, BIOSCAN’s scientific team is preparing new projects.

Website(www.bioscan.cl)

Business Areas


BIOSCAN’s services include human pathogen detection for 50 bacteria, viruses and fungi using PCR techniques. The company has developed a solid logistical system to collect specimens, under quality control conditions, and deliver results to the client. It is a community open clinical laboratory offering a quick and reliable service.

BIOSCAN’s PCR detects 17 viruses in grapes, two in pip fruits and six in stone fruits. It is the only company offering this service to nurseries, fruits and wine producers. There are no alternative methods covering such virus detection.

The laboratory has four segregated areas to perform PCR detection in a reliable way and have Biosafety Level III. BIOSCAN is equipped with conventional PCR and Real Time detection, specimen extraction equipment for human and plant samples, freezers and other laboratory devices.



BiosChile Ingeniería Genética S.A.


Private Corporation96.540.690-5Arturo YudelevichAvenida Zañartu 1482, Santiago


Arturo YudelevichCEO(56-2) 473 6100(56-2) 239 4250 - [email protected]


N°of Employees 65PhD 5Master Degree 15Bachelor Degree 5Technicians and other 40


BiosChile Ingeniería Genética S.A. is a diversified biotechnology company founded in 1986 by a group of leading university professors and local businessmen.Its mission is to be the leader in the use of scientific knowledge for the development of innovative biotechnology products and services in human and animal health. The company develops, manufactures and markets high quality diagnostic tests for the detection of infectious diseases as well as proteins and antibodies for biomedical research.The company also commercializes a full line of reagents, instruments, consumables, equipment and services to support biological research. BiosChile is an ISO9001: 2000 certified Company.

Websitewww.bioschile.cl

Business Areas


BiosChile Ingeniería Genética S.A.’s products cover a wide range of applications and uses, including ELISA tests for Chagas disease, diagnostic kits for fish pathogens and immunofluorescence assays for BKD, SRS and IPNV, urease assays for the detection of Helicobacter pylori in gastric biopsies, blood typing reagents (Anti-A, Anti-B, Anti-AB, Anti-D liquid reagents based on monoclonal antibodies), and custom monoclonal and polyclonal antibodies production.Furthermore, the company has developed a whole line of antigens and antibodies of infectious agents, proteins and antibodies for transcription research, growth factors, cytokines and their antibodies.

BIOT

ECH,

A N

ATIO

NAL

PRIO

RITY

Biot

ech,

a N

atio

nal P

rior

ity


BioSigma S.A.


Private Registered Business Partnership96.991.180-9Ricardo BadillaCasilla 100, Correo El Cortijo, Santiago


Dr Ricardo BadillaGeneral Manager & CEO(56-2) 437 9030(56-2) 460 0416(56-9) 826 [email protected]


N°of Employees 100PhD 15Master Degree 5Laboratory technicians 20Plant operators 10


BioSigma is a closely held corporation owned by CODELCO and Nippon Mining & Metals Co. Ltd. It was established in 2002 in order to develop modern biomining technologies for processing low-grade ores. Its potential is sustained by the wide experience of its shareholders throughout the years. The company employs highly qualified personnel in biotechnology and mineral processing working in state-of-the-art laboratory facilities fully equipped to perform modern genomic and bioleaching work at bench-scale and pilot level.

Websitewww.biosigma.cl

Business Areas


BioSigma is actively involved in R&D and open to third parties only through collaborative agreements in order to develop bioleaching technology for specific ores.At this time BioSigma is not commercializing its products & services in the open market.



Biosonda Corporation


Private Company96.632.300-0Alfredo E. De Ioannes IliEduardo Castillo Velasco 2902, Ñuñoa, Santiago


Alfredo E. De Ioannes IliCEO(56-2) 209 6770(56-2) 274 5462 - [email protected]




BIOSONDA is a private biotechnology company founded in 1992 by Chilean entrepreneurial scientists. BIOSONDA has oriented its business along two main lines: the investigation, development, production and commercialization of biotechnological products for the international markets, and the marketing and distribution of a wide range of products and services in protein chemistry, immunology and molecular biology for research and academic institutions. BIOSONDA’s intellectual property rights includes BLUE CARRIER®, a hemocyanin carrier protein for the production of antibodies obtained from the hemolymph of the mollusk Concholepas concholepas. The Company is organized as follows: - Commercial Area: it is comprised of a sales force with the technical, managerial and computer support

needed for providing quick and efficient services.- Research and Development: Scientists with extensive experience in immunology and protein chemistry

form the staff.- Production and Quality Control: The production facilities are equipped to meet the standards we set for

our R&D work and the products and services we bring to market. - Support and Custom Services: BIOSONDA’s scientific staff is expert in antigen characterization with

polyclonal and monoclonal antibodies and offers counseling in immunobiotechnology. The company has experienced exponential growth and expects to increase 2006’s revenues from US$ 700,000 to two million in the next five years by releasing novel immunostimulants and adjuvants to the market.

Websitewww.biosonda.com

Business Areas


The main BIOSONDA products are immunostimulants, custom-made monoclonal and polyclonal antibodies and red blood reagents for blood banks. BIOSONDA’s service includes real time PCR detection. BIOSONDA also has a line of import products (e.g. reagents for protein chemistry, monoclonal and polyclonal antibodies, kits for nucleic acid isolation, primers for nucleic acid amplification and identification, etc.) Its competitive advantage is related to a number of factors:- Complementary and supportive offerings: Despite the fact that BIOSONDA has a main core offer, it is

heavily supported by other offers such as antibodies and blood reagents, among other key outsourced services.

- Uniqueness: BIOSONDA hemocyanin is a unique substitute over KLH, a market standard. - First mover advantage: Especially with key clients abroad. - Technical Expertise and Knowledge: BIOSONDA has developed unique biotechnological products and

services with worldwide applicability. - High market entry barriers: To compete with BIOSONDA would take more than 30 years of research,

development and industry knowledge.- Flexibility: BIOSONDA is more flexible than its competitors in achieving different solutions according to

their customer’s needs.- Supportive Research: BIOSONDA has completed critical research to determine the advantages (e.g.

molecule structure, molecular bases of its immuno-stimulant capacity, and its characteristics as immunization carrier). This research resulted in BIOSONDA being recently published in the magazine Journal of Biological Chemistry.

For complete information on the company’s products and services, please visit www.biosonda.com.

BIOT

ECH,

A N

ATIO

NAL

PRIO

RITY

Biot

ech,

a N

atio

nal P

rior

ity


Biotecnologías Antofagasta Ltda.


Limited Responsability76.266.650-2María de la Luz Osses KleinAvelino Contardo 920, Antofagasta


María de la Luz Osses KleinProduct Manager(56-55) 385 345(56-55) 385 345(56-9) 817 [email protected]


Biotecnologías Antofagasta was created in March 2005 by two recognized Scientists Dr. Pamela Chávez-Crooker and Mrs. María de la Luz Osses Klein. The company works in two main areas: biomining and water and waste treatment. The main achievements up to date are the signature of 15 medium and long term contracts, preliminary business and marketing plan, setup of the main product lines, and the establishment of the corporative office in Antofagasta.

Business Areas


Biotecnologías Antofagasta Ltda. offers two main services:

1- Integral solutions in the operation and control of water and waste- water processes. The company develops products and services that guarantee the efficiency of water and waste-water treatment plants. It operates in three main areas: a) Processes: It uses biomarkers to assess basic and complex situations that prevent the normal operation of processes, e.g. bulking

and foaming. b) Operations: It developed a methodology for the complete assessment of treatment plants or batch reactors that ensure optimal

operational management.c) Legal: The company provides the necessary legal and technical advice for companies to meet the necessary regulations.

Main areas of contracts:- Assessment, biological and physicochemical control, and monitoring of water and waste water treatment plants- Biotechnological optimization of water and waste water treatment plants and processes related with the use of water- R&D in the application of biotechnological tools in the mining sector - Recovery and reuse of water in mining processes - Operation of water and waste water treatment plants - Legal advice and representation - Training- Audits - Environmental and legal advice

2- Biomining. The company offer a variety of products to copper mining companies that allow them to control biological processes that guarantee efficiency in the decision making process and operations.

There are three main lines of products and services in this area: a) Prospecting: The Company is developing and applying a variety of products that allow it to assess the potential for biolixiviation of

minerals and ores. It evaluates economic outputs of the operations related to the application of biotechnological processes.b) Metallurgical process characterization: after a series of pilot tests, it is able to characterize the best operational conditions of the

bioleaching process. The company designs the engineering profiles and basic operational setups.c) Processes: It offers systematic controls of biological process and batch plants. Applications in the assessment, monitoring and

modeling of biological processes are currently applied. Also, the company develops R&D in the optimization and control of bacterial consortiums for the batch reactors.

Main areas of contracts: - Assessment of minerals and ores. Evaluation of bioleaching potential- Define main criteria for bioleaching process - Monitoring and control of batch reactors- R&D in the application of bacterial consortiums - Biotechnological reagents and materials - Training - Audits - Environmental and legal advice



Websitewww.biotecnologiasantofagasta.com



Biotecnológicas S.A.


Stock Corporation96.945.350-9Jorge Casals CirerAvenida Antonio Varas 1323, Providencia,Santiago


Rafael Karque OrtegaDevelopment Manager(56-2) 274 1863(56-2) 269 2436(56-9) 959 [email protected]




Biotecnológicas is based in Santiago, Chile. Its main activity is innovation and technology management within the biotechnological sector. Biotecnológicas works as a service provider, research and development partner and spin-off partner for our customers. It started its activities as a Stock Corporation on February 16, 2001. The company looks for the creation of new businesses by solving current and future problems of the biotechnological sector, as well as by identifying current and future opportunities for particular companies using biotechnology, technology monitoring, and connectivity networks as our main tools for technology management. As a result of these tools applications, discovered business opportunities are rapidly translated into new products, changes on technological practices, reutilization of industrial by-products and waste materials, and optimization in the use of natural resources.The company works on the creation, management and development of R&D projects in Aquaculture (Biofeed, Antifouling), Industrial Waste utilization (Fish Gelatin, Hyaluronic Acid, Growth Hormone, Taurine, Lactic Acid, Apple Fiber and Wax), Agriculture (Biofertilizing, Antiviral, genetically modified Eucalyptus) and Mining Industry (Biomin) sectors. It also provides training in key business and management skills such as Six Sigma NPI decision-making system.

Websitewww.biotecnologica.cl

Business Areas


The company is focused on the generation of research, development and innovation projects to be applied to real market needs and searching for products or process for the export market. All of its products and services are designed with a global vision that generally involves the potential generation of new businesses or spin-off companies. The difference between the company and its indirect competition, universities or research centers, comes from the applied approach to solving problems directly related to market needs.Biotecnología S.A. provides services in scientist-technical, commercial, legal and management areas, and has the capacity to identify and hire a whole range of highly qualified experts to develop each project. The company uses a variety of tools such as: biotechnology, connectivity networks, monitoring and technological prospecting, and applying the Six Sigma-NPI decision-making system throughout the process.

BIOT

ECH,

A N

ATIO

NAL

PRIO

RITY

Biot

ech,

a N

atio

nal P

rior

ity


Biotecnor Ltda.


Private Company77.843.040-1Williams SaavedraAvenida Angamos 0610, Antofagasta, Chile


Cecilia DemergassoTechnical Manager(56-55) 355 622(56-55) 355 496 - [email protected]


Biotecnor Ltda., founded in 2002, is a spin-off enterprise composed by a group of five researchers who work in the Laboratory of Technical Microbiology (LMT), Universidad Católica del Norte (UCN), Antofagasta, Chile.Biotecnor Ltda. has been doing work related to mining microbiology since its founding. The organization activities are research, development, innovation, monitoring services, training and professional assistance in biotechnology and geomicrobiology. The service portfolio includes: evaluation and characterization of microbial communities, bioleaching tests, search of exploitable biological material, development and innovation in biotechnological processes. The company’s average annual sales (2003-2005) are USD $120,000.

Business Areas


Using modern biological techniques the company has developed and transferred new methods to the economic production sector through advanced biotechnological services. Developments include monitoring techniques and selective cultures for industrial bacterial leaching processes that will improve and optimize bioheap or dump leaching performance. Services are offered in the field, avoiding changes in dynamic bacterial communities. Its services are characterized by accuracy and fast response.


N°of Employees 6PhD 2Technicians 7Bachelor Degree 4

Websitewww.lmt.cl



Bio Tritón S.A.


Business Partnership96.999.840-8Juan Pablo Schmidt JobetAvenida El Golf 192, Apt 115, Las Condes, Santiago


Juan Pablo Schmidt J.General Manager(56-2) 334 6958(56-2) 334 6958(56-9) 888 [email protected]


N°of Employees 5PhD 2


Bio Tritón S.A. represents European enterprises (AMYKOR GmbH and MYCOSYM International AG) related to the production of biofertilizers such as MYCORRHIZAS (VAM).Bio Tritón imports and distributes products which are used in agriculture, horticulture, forestry, home gardening, landscaping, revegetation of mines and contaminated areas, dumps, environmental solutions, etc.

Websitewww.biotri-ton.cl

Business Areas


Bio Tritón provides field support. The competitive advantages of Bio Tritón’s products are concentration and long-term shelf life. Special products are also manufactured upon specific request.

BIOT

ECH,

A N

ATIO

NAL

PRIO

RITY

Biot

ech,

a N

atio

nal P

rior

ity


C.G.M. Nuclear S.A.


Public Limited Company96.757.080-KMaría Cecilia Gil ValenzuelaCasilla 215, Correo 12, Santiago


María Cecilia Gil ValenzuelaCEO(56-2) 271 8970(56-2) 271 9485(56-9) 239 [email protected]


Former professionals of the Chilean Atomic Energy Commission formed C.G.M. Nuclear S.A. in 1995. Since C.G.M. Nuclear’s inception in the market, twenty radiopharmaceuticals and radiodiagnostic products have been developed and produced. C.G.M.’s research in radiopharmacy on a national level led to the development of nuclear medicine as a diagnostic and therapeutic tool. Scientific research is the main goal of this company, as well as the production and distribution of radiopharmaceuticals and the development of new radiopharmaceutical and radiodiagnostic products. Current research activities include Radiochemistry and Radiopharmacology of Technetium Complexes, Peptide-radiolabeling technology, use of Monoclonal and Polyclonal Antibodies for in-vitro applications, Therapeutic Radiopharmaceuticals, etc.

Business Areas


CGM Nuclear’s products are radiodiagnostic and radiotherapeutic agents used in nuclear medicine. The products are kits for on site preparation or labeling with Tecnetium-99m to be used as Diagnostic Radiopharmaceutical in Nuclear Medicine Departments. CGM Nuclear provides educational programs in radiopharmacy and radiology protection for technical personnel of hospitals and biomedical laboratories. CGM Nuclear facilities meet all requirements to be certified by GMP. CGM Nuclear uses radioisotopes and biological molecules (peptides) that are not produced in Chile.


N°of Employees 10Master Degree 2Bachelor Degree 3Administrative 5

Websitewww.cgmnuclear.cl



Clarke Modet & Co.


Partnership78.773.320-4Carolina del RíoHuérfanos 835, 10th Floor, Santiago


Carolina del Río and Eugenia OlivaresGeneral Director and Patent Technician(56-2) 369 9888(56-2) 360 9050 - [email protected],




Clarke, Modet & Co. helps organizations to protect their Intellectual Property Rights from the early stage of the creation or design all the way through its use and protection. Established in Spain in 1879, Clarke, Modet & Co. is a leading firm providing expert advice on intellectual property matters in Spanish and Portuguese speaking countries. The expertise is built on a combined 127 years of experience in this field. With a network of offices in Spain, Portugal, Argentina, Brazil, Chile, Colombia, Mexico, Peru, and Venezuela, the company is focused on delivering quality and value whilst keeping ahead of the changing needs of the different industry sectors. It specializes in patents, technology transfer, plant varieties, denominations of origin, and unfair competition, among others. A team of 400 highly experienced and dedicated engineers, biologists, chemists, economists and lawyers assists more than 8,000 clients from all over the world.

Websitewww.clarkemodet.com

Business Areas


- Filing of patents, trademarks, copyright and plant varieties applications, denominations of origin, unfair competition and Internet domains.

- Consultant services regarding Intellectual Property as well as guidelines for Research and Development, and technology transfer

- Technical Searches regarding State of the Art of a specific area.

BIOT

ECH,

A N

ATIO

NAL

PRIO

RITY

Biot

ech,

a N

atio

nal P

rior

ity


Colmenares Santa Inés S.A.


96.578.680-5Private organizationAlberto Poch FrismannRuta 5 Sur Km. 182, Curíco, Chile


Paula Landeros SilvaSales Manager(56-75) 380 776(56-75) 380 775(56-9) 746 [email protected]


Colmenares Santa Inés S.A.’s has more than 75 years of apiculture operation. The company scale of operations is 4,500 hives.

Business Areas


Colmenares Santa Inés’ products are organic honey and natural honey. Through experience and service, the company provides a different service than its competitors. The main competitive advantages are traceability and periodic technology improvement.The honey production is organic; therefore the effort is focused on the bees’ resistance to pests and diseases. The harvest is done in a modern plant. Colmenares Santa Inés expects honey production of 250 tons for the next three years. The company’s suppliers are: Comercial Kaufmann S.A. for all mechanical parts; Institut für Biennenkunde, and Austria for the genetic bee material.



Website-



Criadero Nueva Suiza Ltda.


Family Business88.924.700-2José PetermannCasilla 3148, Concepcíon, Chile


José PetermannGeneral Manager(56-41) 340 823 - - - - - -


N°of Employees 53Master Degree 1Bachelor Degree 2Operators and 50Technicians

Organization DescriptionCriadero Nueva Suiza (CNS) breeds bovines and equines, and focuses on the production of four different products:(1) Bovine Milk - sold to Nestle (2) Bovine Milk Cream - sold in Chile for manufacture of prime frozen desserts(3) Equine Serum, young and Adult- sold to the European Union (4) Equine Plasma, pregnant mares - sold to the European Union All products are produced at the 500 acres Nueva Suiza Field. The property is located 365 kilometers south of Santiago. Bovines and equines are managed separately to ensure appropriate care, males and females are separated according to business practices.CNS has permanent pastures, with no plowing or massive use of pesticides. Equines always graze in freedom. Reproduction, gestation and lactation are not artificially forced. During the gestation period donations of serum and plasma are scheduled for collection of PMSG and several hormones. Donations are processed in two labs; one specializes in plasma and the other in serum. The labs are maintained under strict aseptic sanitary conditions in order to comply with quality standards defined by European clients.Most company policies, procedures and operational norms are written down. The executive team has worked hard to ensure all employees understand standards. Special attention has been put into training supervisors. CNS believes the application and use of policies, procedures and norms is essential to be successful.

[email protected]

Business Areas


For the biotechnology industry CNS offers two products: - Equine Serum: donated aseptically from mares, young colts and fillies, immediately frozen to -20º C,

placed in gallons and tested to ensure it is free of endotoxins. The serum is used in human health and tissue growing.

- Plasma: separated from different donations than serum, from pregnant lactating mares after breeding and frozen in buckets.

Also several hormones (PMSG, equine conjugated oestrogens, oestradiol, progesterone, etc). CNS products are different from artificially synthesized products (with doubtful quality due to impurities and synthesis of compounds or similar molecules but with different effects), coming from slaughterhouses exposed to cross contamination difficult to trace or places not free from encephalopathies (TSE). Chilean authorities certify that both products are naturally produced from donor, live and free kept livestock in optimum body and health condition, under the supervision of a veterinary, reproducing naturally and pregnant up to birth. They also certify that CNS is free of any encephalopathy (TSE), especially BSE, complying with stringent requirements for equidae serum (including being disease free of 9 other diseases affecting horses around the world) to enter the European Union. The company has been exporting it for several years and its current production is up to 20,000 kg/year.

BIOT

ECH,

A N

ATIO

NAL

PRIO

RITY

Biot

ech,

a N

atio

nal P

rior

ity


Diagnotec S.A.


Private78.957.810-9Geraldine Mlynarz and Ana María SandinoGeneral del Canto 460, Providencia, Santiago


Geraldine MlynarzCEO(56-2) 236 3022(56-2) 236 [email protected]


DIAGNOTEC is a biotechnological company specialized in diagnosis and control of infectious diseases that cause huge economic losses in animal production. The mission of the Company is to develop and promote massive use of biotechnological tools at convenient cost to improve and increase the efficiency of productive systems.Using advanced technology, DIAGNOTEC. has developed and offers services for molecular diagnosis of relevant pathogens in aquaculture, porcine and food industry. Diagnosis tools for plant viruses are currently under development.

Business Areas


- Molecular Diagnosis of Pathogens: Salmon viruses (IPNV, IHNV, ISAV) and bacteria (BKD, SRS, Flavobacteium spp.) from blood, tissues, eggs, ovary and seminal fluids, Pig viruses and bacteria (PRRSV, Mycoplasm) from blood, serum, tissues, feces and vectors such us flies. Food bacteria (Listeria monocytogenes, Salmonella spp. and E coli O157:H7)

- Immunological Diagnosis of Pathogens: ELISA and IFAT for salmon bacteria (BKD and SRS mainly) - Genetic Variability Analysis: Molecular analysis of microsatellites in order to minimize problems

associated to salmon inbreeding.- Genetic Programs: Programs of genetic improvement, including molecular technologies that allow

assisted selection of breeders in salmon coho, salmon salar, and trout.- Biological Evaluation: Evaluation of vaccine and compounds with biological activities in fishes.

Evaluation of neutralizing antibodies (serum titles) post vaccination in salmon. Evaluation of antiviral compounds and disinfectant efficiency in cell culture.

- Other Services: Sex determination in salmon and ostriches. Analysis of Ploipdia in salmon.



Websitewww.diagnotec.cl



Ecoforce S.A.


Business Partnership.99.588.160-8Juan Pablo Schmidt JobetAvenida El Golf 192, Apt. 115, Las Condes, Santiago


Juan Pablo Schmidt JobetGeneral Manager(56-2) 334 6958(56-2) 334 6958(56-9) 888 [email protected]


N°of Employees Bachelor Degree 5


ECOFORCE is focused on finding solutions for the environmental problems caused by odors produced by factories, industries of different kinds, dumps, water and mud treatment plants, alimentary industry, etc.

Website www.ecoforce.cl

Business Areas


ECOFORCE offers two types of measurement of odors, at the source and in the surrounding. These are made by instruments and sensorial measurement. Also the company offers technical support to eliminate the odors. The products ECOFORCE uses (biological industrial essential oils) are purchased at an official distributor

BIOT

ECH,

A N

ATIO

NAL

PRIO

RITY

Biot

ech,

a N

atio

nal P

rior

ity


Ecotecnos S.A.


Private77.269.460-1Benjamín Patricio Araneda HerreraQuillota # 1140, Viña del Mar, Chile


Benjamín Patricio Araneda HerreraCEO(56-3) 248 1851(56-3) 248 1851(56-9) 319 [email protected]


EcoTecnos was founded in 1998, initially conceived to provide management services, assessments, transactions and environmental counselling. EcoTecnos is considered among environmental consulting companies as a pioneer in Environmental Biotechnological applications. The company’s first product AquaBact® was created for application in remedial techniques in land contaminated with hydrocarbons and crude oil derivatives.The company has a staff of highly qualified professionals who stand out in the academic and private scope. The knowledge of its professionals and their restlessness to innovate has made it possible to develop biotechnological products applicable in the Agricultural field (Plague Controllers, Biostimulants and Biofertilizers), in the farming and animal industry (Probiotic which removes Salmonella from poultry farms) as well as other other industries. At present, the company’s laboratories have a weekly production capacity of 600.000 doses of Probiotics and supplies the main poultry-breeding enterprises in Chile. The Company also produces a weekly supply of biofertilizers and plague controllers sufficient for 300 hectares.

Business Areas


The environmental division offers environmental management services, but it also offers services complying with advanced technology. In this context, it offers the satellite detection of hydrocarbon contaminants in land and subterranean waters with depths in excess of 50 meters dating back 20 years.The biotechnological division has developed products based on specific characteristics of microorganisms. It produces the following products: - ProbiBact®, probiotic that removes Salmonella from poultry farms;- AquaBact® , microbiological consortium capable of degrading hydrocarbons from crude oil, land and

water contaminants;- FertiBact® microbiological consortium, which fixes environmental nitrogen, solubilizes mineral salts

and stimulates the routes of plants;- BioThric® a product based on Trichoderma able to control plague funguses in plants; - BioMet® and BioBau®, products based on Metarhizium and Bauveria respectively, capable of

controlling insects’ plagues; and - FitoMax, bio stimulant of vegetal growth, of folious application.



Websitewww.ecotecnos.cl



Eugenio Marín S.A.


Private Laboratory96.845.060-3Eugenio Marín V.Avenida Apoquindo 4900, Local 178, Santiago


Eugenio Marín V.Director(56-2) 211 5668(56-2) 220 6001(56-9) 138 [email protected]


N°of Employees 12Bachelor Degree 1Technicians and Operators 11


Eugenio Marín is a laboratory with two principal sections: Sensidiscs and Multidiscs Antibiotics. Sensidiscs are manufactured manually; multidiscs are robotized.

Websitewww.sdachile.com

Business Areas


Eugenio Marín products are:- Sensitivity Discs of Antibiotics - Software for Microbiology Laboratory- Multidisc of AntibioticsEugenio Marín is an ISO 9001:2000 (SGS) company. Procedures and registrations comply with total quality standards. Its products are manufactured with a Robotic Arm System. Also the company uses CLSI processes (Clinical and Laboratory Standards Institute practices).

BIOT

ECH,

A N

ATIO

NAL

PRIO

RITY

Biot

ech,

a N

atio

nal P

rior

ity


Flores y Acevedo Abogados y Consultores Ltda.


Limited Responsibility Society76.229.620-9Jose Miguel Flores AcuñaVictor Lamas 1099, Concepción, Chile


José Miguel Flores AcuñaAttorney, partner(56-41) 791 493 / 498- -(56-9) 442 [email protected]


Flores y Acevedo is a law firm specialized in Intellectual Property Law, Technology Transfer, Corporative Law, Tax Law, Accountancy, Organizational Development, and Corporative Image.It has alliances with many particular professionals in Chile and abroad and takes complete care of clients needs.The firm is the only specialized law office dedicated to Intellectual Property Law and Technology Transfer located outside Santiago, capital of Chile.

Business Areas


The primary services are related to the protection of Biotechnology innovations, via patents, utility and industrial models, trademarks, trade secrets, copyrights, and obtainer rights.The firm also includes services related to obtain the best economic results for the clients, especially in Taxes and Corporative Law in general (i.e. tax planning when Technology Transfer is done).The company is different from its competitors because of its expertise and multi-disciplinary team.



Websitewww.floresasesorias.cl



Fumigaciones y Exportaciones Ltda.


Private Fund78.073.250-4Eduardo ConcaClemente Fabres 918, Providencia, Santiago


Eduardo ConcaDirector(56-2) 274 6068(56-2) 204 2261(56-9) 821 [email protected]


N°of Employees 14Master Degree 1Bachelor Degree 4Administrative and Operational 9


FUMEX is a Chilean company formed by agronomists, dedicated to the development and diffusion of high technologies to obtain the maximum quality and productivity in vegetal species of economic importance. The company has more than 15 years of experience in this field, applied to the national and international markets.FUMEX’s product line include: - Natural BioRegulators (natural vegetal hormones that produce desired and defined states in the

plant), - BioStimulating (helps the plant to surpass stress state and develop in a productive way) and - BioFertilizers (beneficial micro organisms that stimulate plant productivity). All are clean products that protect the environment, population health and may be applied both in conventional or organic agriculture.

Websitewww.fumex.cl

Business Areas


FUMEX’s main products are: - Organic fertilizer that is useful as nutritious substrate for microorganisms- Nutritive product based in yeasts and minerals for animal production- Mycorrhizal inoculant- Cellulose digesters to accelerate the composting process- Microorganism for fertilizing (20 bacteria)- Microorganism for bio control (control of Naupactus xanthographus, nematodes)The products are different from its competitors because they are innovative and effective. The principal advantages of the FUMEX products are: Innovation, lower cost and effectiveness.The company has two plants, one with a drying spray tower that produces hydrosoluble products, and another with bioreactors. The facilities include: - Productive Plant, located in Quilicura, Santiago. - Productive Plant, located in Lampa, Santiago. - Laboratory, located in Providencia, Santiago. FUMEX is looking for strategic alliances for commercializing its products in other countries.

BIOT

ECH,

A N

ATIO

NAL

PRIO

RITY

Biot

ech,

a N

atio

nal P

rior

ity


Fundacion Biociencia


Private Non-Profit Research Institute65.061.210-8Olivier Rickmers GueydanJosé Domingo Cañas 2280, Ñuñoa, Santiago


Olivier RickmersPresident and Legal Representative(56-2) 343 2578(56-2) 343 2578(56-9) 844 [email protected]


Fundación Biociencia is the leading institution on Extremophiles Research and Development in Chile. The organization interacts globally with companies and academic research centers that require specialized knowledge of microorganisms from extreme environments and their bioactive compounds.In this highly specialized domain, the Foundation focuses its efforts on the isolation of extremophiles from their natural sources and the discovery and purification of their original bioactive compounds, particularly novel enzymes of biotechnological potential. Fundación Biociencia has unmatched expertise in cultures, DNA extraction and enzyme purification from extremophilic microorganisms.The organization provides industrial R&D services to partners and customers that need access to the original, newly found extremophilic microorganisms and their natural bioactive compounds, in order to maintain their competitive edge or enter into new markets.Fundación Biociencia researches topics such as geomicrobiology, desiccation resistance, heavy metal resistance and transformation or search for nanoarchaea. These projects are carried out in collaboration with scientific groups from USA, South Africa, Spain, France, Germany, Russia, Brazil and Chile.

Business Areas


Fundación Biociencia’s core offerings are specialized services in Extremophiles R&D. They include sampling from natural extreme environments, growth and isolation of extremophilic microorganisms, and the detection, purification and characterization of their bioactive compounds.Fundación Biociencia has achieved very skilled competences in the last few years, focusing on extremophiles with uncommon growth conditions. These microorganisms may escape detection when traditional screening techniques are applied to environmental samples. Therefore, DNA extraction and protein purification require methods that are challenging to develop. Also, the Foundation has a growing group of its own isolates, sampled from hot springs, salt lakes, deserts, heavy metal contaminated environments, Antarctica and similar environments



Websitewww.bioscience.cl



Fundación Chile


Private Non-Profit Organization70.300.000-2Javier Duarte García de CortázarAv. Parque Antonio Rabat Sur 6165, Vitacura, Santiago


Claudio MaggiDevelopment Manager(56-2) 240 0304(56-2) 241 9387- [email protected]




Fundacion Chile’s mission is to add economic value to Chilean products and services by promoting innovation and technology transfer aimed at taking advantage of Chilean natural resources and productive capacity. Since 1997 the use of biotechnology to help achieve this mission has been a strategic focus. For further details, visit our web site: www.fundacionchile.cl

Websitewww.fundacionchile.cl

Business Areas


Fundación Chile products and services include technology services, diffusion & training, product & process innovations and business incubation.Fundación Chile is unique, because it is a non-profit institution with an active participation in the creation of innovative private companies, participating in the entire range of activities including technology services, R&D, creation and incubation of companies, seed capital, scale-up, and financial innovation.The areas of biotechnology include recombinant proteins, tissue culture, molecular genetics, functional genomics, genetic engineering, and aquaculture. A recombinant protein vaccine for salmon developed in collaboration between Fundación Chile and Fundación Ciencias para la Vida has been licensed to Syngenta and is being introduced in the market. Elite clones of radiata pine developed through somatic embryogenesis in collaboration with CellFor are in advanced testing stages and will be introduced in the market soon through a Fundación Chile company, GenFor. Other Fundación Chile biotechnology programs are in early R&D stages.Fundación Chile seeks opportunities to strengthen its existing biotechnology programs and establish new programs in areas of specific strategic importance in Chile.

BIOT

ECH,

A N

ATIO

NAL

PRIO

RITY

Biot

ech,

a N

atio

nal P

rior

ity


Fundación Ciencia para la Vida


Private - Non Profit Foundation73.124.100-7Pablo ValenzuelaAvenida Zañartu 1482, Santiago


Mario RosemblattExecutive Director(56-2) 239 8969(56-2) 237 2259- [email protected]


The Foundation’s goal is to stimulate the use of biotechnology by the Chilean productive sector, specifically by export-oriented industries with high economic impact. In this context, the Foundation acts as a bridge between the productive and academic sectors in the country and with international players abroad.The Foundation aims to establish itself as a leader in biotechnology, through its:- In-house research and development programs in collaboration with the private sector using

biotechnology to solve problems that affect the main Chilean export industries.- Educational and training activities in biotechnology, focused on developing the professionals of the

future by participating in undergraduate and postgraduate programs of selected universities.- Broad network of international collaborations with biological sciences and biotechnology leaders in

the fields of interest to Chile, aimed at identifying and obtaining available resources required by the local biotechnological efforts.

- Participation as a “think-tank” in the development of national strategies and policies in science and technology, with a special emphasis in biotechnology.

Business Areas


With a strong emphasis in biotechnology, the Foundation has accomplished very effective associations with several organizations from the Chilean private and public sectors, working on solving problems with high economic impact. In this regard, its advances in R&D are being widely welcomed by these sectors as reflected by the fact that investigators from several institutions often approach the Fundación to initiate new collaborative efforts. This is having a significant impact on the way both private and public institutions are viewing the importance of this targeted research. Over the last five years, its R&D activities have produced more than 10 patent applications, and 53 original publications. In addition, during this period the Foundation’s members have participated in more than 80 keynote addresses, conferences and symposia, and have received several awards.


N°of Employees 43PhD 10Veterinarian 1Master Degree 10Accountan 1Secretary 4

Websitewww.cienciavida.cl



Genética y Tecnología Ltda.


Private Organization78.340.830-9Monica Acuña Patzke, Lucia Cifuentes OvalleCoronel Santiago Bueras 160-A, Santiago Centro, Santiago


Hugo JorqueraLaboratory Director(56-2) 633 1619(56-2) 639 3124(56-9) 459 [email protected]


N°of Employees 8Master Degree 2Bachelor Degree 1Technician 1Secretary 1


GENYTEC is a molecular biology products distributor, which also provides services in their molecular genetics laboratory. These services include paternity analysis, sequencing and primer synthesis.

Websitewww.genytec.cl

Business Areas


GENYTEC provides a wide range of services, from sales of molecular biology enzymes, cell signaling and antibodies products to human molecular diagnosis and paternity analysis. GENYTEC also provides such services as automated sequencing and primer synthesis.

BIOT

ECH,

A N

ATIO

NAL

PRIO

RITY

Biot

ech,

a N

atio

nal P

rior

ity


GenFor S.A.


Private96.890.990-8Javier Duarte García de CortázarGCL - Fundación Chile, Marco Polo 9038, Office A, Complejo FlexCenter, Hualpén, Concepción, Chile


Juan Carlos Carmona S.Operation Manager(56-9) 089-5961 --(56-9) [email protected]


GenFor is focused on commercial applications of biotechnology and genetic improvement of forestry trees, in particular the radiata pine.

Business Areas


GenFor has developed elite clones of radiata pine in collaboration with CellFor and have been in field tests since 2000. The clones are currently being scaled up, and will soon be available in the market.GenFor offers services in tissue culture, clonal development and micropropagation of radiata pine and other woody species



Websitewww.fundacionchile.cl



Industrias Grasas y Aceites Ltda.

Ownership and Structure

Registration NumberLegal RepresentativePostal Address

Private Business Partnership; Limited Liability Partnership76.432.210-KPedro Javier Eraña FanoLago Llanquihue 03172, San Bernardo, Santiago


Pedro Javier Eraña FanoVice Chairman & Director(56-2) 854 3441(56-2) 854 2880(56-8) 228 [email protected]


N°of Employees 15Bachelor Degree 4Technicians and administrative 11


INGRAS is a new company in the energy-fuel sector. The company invented a product called “biofuel”, which is made from recycled oil and fat. The company is the result of a scientific investigation project funded by the Chilean Economic Development Agency (CORFO) through the financing of the National Technology Fund (Fontec).INGRAS has production, storage and commercialization biofuel installations, in a 6,000 m2 facility. Most of the company’s process is automated.INGRAS’s corporate structure is simple: a partnership of two members who are owners of all the installations. The partners conduct all the business.

Websitewww.ingras.cl

Business Areas


INGRAS has all the necessary facilities for biofuel production by discontinuous method. The company has developed the technology to use waste oil and fat as raw materials. Virgin oil and others fats can also be used.INGRAS has a tank storage capacity of 2,000 tons for raw materials and final product. Monthly production is 300 tons of biofuel.

BIOT

ECH,

A N

ATIO

NAL

PRIO

RITY

Biot

ech,

a N

atio

nal P

rior

ity


Laboratorio Centrovet Ltda.


Limited Liability Company86.510.400-6David FarcasAvenida Los Cerrillos 602, Cerrillos, Santiago


David FarcasCFO(56-2) 557 6062(56-2) 533 1186(56-9) 238 [email protected]


CENTROVET is a Chilean company working in animal health and pharmaceuticals since 1979.CENTROVET’s major clients are the leading meat (poultry, swine, cattle and fish), eggs and milk producers in Bolivia, Costa Rica, Chile, Colombia, Ecuador, Jordan, Korea, Lebanon, Malaysia, Moldova, Nepal, Nigeria, Pakistan, Paraguay, Peru, Dominican Republic, Syria, Turkey, Ukraine, Uruguay, Yemen, and Venezuela.CENTROVET’s business strategy is based on cutting edge technology, innovative, outstanding R&D and QC. All products are manufactured according to Good Manufacturing Practice regulations.

Business Areas


CENTROVET’s main products are:- Anti-infective,- Antiparasitic,- Vaccines,- Anesthetics,- Anti-inflammatory,- Analgesics,- Disinfectants,- Feed additives,The company also provides liquid products such as disinfectants, oral solutions, injectable solutions, suspensions, and shampoos.CENTROVET has important pharmacokinetic and pharmacodynamic differences from its competitors’ products and has lower prices.Main raw material suppliers are from China. The production capacity is not sufficient for the current demand, so CENTROVET needs to invest in biotechnology equipment.


N°of Employees 155PhD 2Master Degree 3Bachelor Degree 20Pharmacists 3Veterinarians 15Biologists 2

Websitewww.centrovet.com



Laboratorio Linsan S.A.


Private Company80.528.300-9Jorge Morgado A.Pedro de Valdivia 3078.1, Santiago


Loreto Gardeweg MontenegroTechnical Manager(56-2) 223 9462(56-2) 223 8329(56-9) 129 [email protected]


N°of Employees 17PhD 1Master Degree 1Bachelor Degree 4Other 11


Laboratorio Linsan is a biotechnology laboratory, which produces microbiology media and supplies for clinical, veterinary, hygiene, food and beverage control areas. The company is certified ISO 9001-2000.

Websitewww.lablinsan.cl

Business Areas


Laboratorio Linsan’s products are ready to use microbiological culture media/technical service processes used in microbiology control in clinical medicine, food & beverage, veterinary medicine & hygiene areas.The company’s products are manufactured in Chile, with superior shelf life and distributed fresh to customers. Optimal plant, equipment and on- line technologies have been developed. The difference with its competitors is the technical assessment and manufacture of special products tailored for each of its customers.

BIOT

ECH,

A N

ATIO

NAL

PRIO

RITY

Biot

ech,

a N

atio

nal P

rior

ity




Family Company82.524.300-3Roberto ArrietaCasilla 81, Los Cerrillos, Santiago


Hugo ZuninoResearch and Development Manager(56-2) 384 4079(56-2) 384 4020(56-9) 816 [email protected]


VETERQUÍMICA, through its pre-mix industrial plants is organized to produce pharmaceutical (biologics and pharmacological ones), mineral and vitamins pre-mixes and disinfectant products for animal meat producers mainly poultry, swine, bovine and ovine cattle, pet and salmon industries. A high proportion of these products correspond to own-developed and/or own-formulated ones. At present, the main interest relies on the development of innovative biological products, i.e. vaccines and inmunostimulants for salmon and cattle, and urea blocks with coccidiostatic formulations. For these products the company foresees multiple exportation markets.VETERQUÍMICA exports around 10 % of its production to Peru, Bolivia and Paraguay.

Business Areas


VETERQUÍMICA differs from the competition in that the company has innovative, pharmaceutical and nutritional products for use with animals with sounds scientific support. The company also has highly proven field efficiency and safety with special properties.Services include: - Traditional fermentation procedures. - Tissue-culture processes.- Automatic pre-mixes processes. - Hot compactation blocking methodology. VETERQUÍMICA seeks integral support onto international sales through commercial and technical representations.



Websitewww.veterquimica.cl



Private CompanyIn ProcessAndres Antonio Leschot SanhuezaMonseñor Escrivá de Balaguer 9547, Office 1003B, Vitacura, Santiago

Lucien Biotechnologies



Alvaro Olivera-NappaDirector(56-2) 474 0690--(56-8) 429 [email protected]




Lucien Biotechnologies was officially established in 2006, after four and a half years of previous product development and successful field tests. The main goal of the company is to increase the quality and value of foods, especially in order to enhance and promote the benefits that they contribute to the consumer’s health and well-being.

The company’s first objectives were to improve visual characteristics and quality of fruits, particularly apples. Lack of good natural coloring in apples as well as damage produced by excess solar radiation greatly reduces market fruit price and strongly affects the loss of an important portion of production.

LUCIEN’s technology enhances a fruit’s natural protection response making it able to better defend itself. The company’s first products improve color development and decrease sunburn damage in apples, causing less production loss and dramatically increasing revenues for the producer.

LUCIEN’s innovative technology enables flavonoid biosynthesis modulation inside plants. This is a technological platform that uses no transgenic techniques to produce such results, by giving plants adequate biochemical signals and means, and is fully protected by broad international patent applications. This platform was awarded first place in World’s Best Technologies 2006 Showcase (Texas, USA).

Websitewww.lucienbiotech.net

Business Areas


LUCIEN developed two products that improve color and decrease sunburn damage in apples. To date, products developed to protect fruits from sunburn consist basically of solar filters or sunscreens and there is not a single product on the market that actually solves both problems. The core products are elaborated from agricultural waste and they are designed to target specific flavonoid biosynthesis in a non-transgenic way.Currently, the company is developing an optimized version for application on other fruits. Additionally, its creating a new family of products that increase vegetable nutritional value and transform them into functional foods by increasing their flavonoid and polyphenol contents and improving their antioxidant properties (not available commercially yet). These treatments will ultimately be able to dramatically increase the content of one or more specific targeted flavonoid molecules in plant tissues. LUCIEN is also evaluating a more cost-effective and efficient production processes for its products.


Azul, Amarillo y gris

1969Employees 150PhD 4

BIOT

ECH,

A N

ATIO

NAL

PRIO

RITY

Biot

ech,

a N

atio

nal P

rior

ity


Mygoldex Chile Ltda.

Ownership and Structure

Registration NumberLegal RepresentativePostal Address

Private Company Wholly Owned by Microbix Biosystems Inc. of Toronto, Canada.59.105.610-7Dr. Liliana Corvalán DobryAvenida Las Torres 5150, Hospital Santiago Oriente, Santiago


Dr. Gareth I. OwenManager/ Technical Director(56-2) 467 3032(56-2) 472 [email protected]


MYGOLDEX provides services in tissue processing and cell banking to South American-based biotechnology, pharmaceutical / vaccine and academic institutions from Santiago, Chile. MYGOLDEX Chile is a subsidiary of Microbix Biosystems Inc. a biopharmaceutical company located in Toronto, Canada.MYGOLDEX wishes to collaborate with the Chilean Health Network supporting biotechnology product research and manufacturing for the US market. The company works under Good Manufacturing Practices (GMP) regulations according to international standards and is inspected routinely by North American collaborators. The company provides services in cell banking using environmentally controlled clean rooms and equipment under GMP control and provides custom cells preparations from tissue or client samples. Activities include preparation of cell suspensions from tissues, cultures, cryopreservation in liquid nitrogen, cell bank characterization, storage and documentation.

Business Areas


MYGOLDEX currently provides cell banking for human and animal for use in the biotherapeutic market. Operations are currently located in our facility in the Hospital Santiago Oriente in Santiago, Chile.MYGOLDEX offers a South American-based alternative to North American and European based organizations. The company’s goal is to improve services by offering them on a timely basis with reduced cost compared to US providers. Processes employed include: tissue digestion, creation of cell banks, cell culture, cryopreservation. Activities are carried out in validated facilities with qualified equipment including clean rooms, LN2 cryopreservation freezer, centrifuge, and controlled storage equipment. As a start-up company MYGOLDEX recognizes the need for good communication with clients and vendors to ensure timely delivery of critical raw materials and finished products. Open lines of communication are critical with governmental agencies in order to fully understand legal / governmental regulations to expedite permits, licensing, etc. Timely resolution of these issues is critical to business success and our relationship with customers. The organization is based on a network of vendors that must provide high caliber services in areas such as equipment calibration and maintenance, validation and raw materials testing.


N°of Employees 7PhD 2Medical Doctors 2Bachelor Degree 3

Website-



NEOS, Servicios de Gestión Tecnológica Ltda.


Private and Registered Business Partnership76.015.940-9Allan Jarry FloresIsidora Goyenechea 3250, 3rd Floor. Las Condes, Santiago


Jorge FuentesGeneral Manager(56-2) 439 7770(56-2) 439 7777(56-9) 841 [email protected]




NEOS is the only private firm in Chile oriented towards the management and transfer of technology. Its a self-sustaining spin-off of Estudio Harnecker, one of the oldest and largest national firms dedicated to Intellectual Property Rights. Created in 1910, and with a staff of close to 50 professionals, Harnecker handles approximately 20% of all patents filed in-country. However, NEOS was born within the past four years to fulfill a recognized inefficiency; the lack of Chilean technologies reaching the abroad developed world.NEOS has a working relationship with universities, research centers, private companies, as well as professional member-associations. At the same time, NEOS plays an active role in national policy establishment and in the state of science, technology, and innovation within the country.Areas of concentration include: the transfer of technologies; IP and technology transfer education; the uniting of Chilean innovative minds with international counterparts; the creation of seminars to enlighten and enhance the knowledge of local universities, government, private industry, and innovators; the management of government funds for innovation competitions in order to protect IP rights; as well as other opportunity-matching events to increase the technology interaction in Chile.

Websitewww.neos.cl

Business Areas


Primary focus for NEOS is technology transfer. In doing so, the group is partnered with 17 universities, as well as many small and medium enterprises (SMEs), and individual researchers as well. Depending on the client, services include: prior art searches, patentability analysis, finance searches, market reports, contract drafting, and successfully finding and licensing technologies.In being linked with so many universities, SMEs, industry organizations, and governments, NEOS also poses as the link between the outside world and Latin America. This includes technology demand searches, technology surveillance, and partnering opportunities with regional experts.

BIOT

ECH,

A N

ATIO

NAL

PRIO

RITY

Biot

ech,

a N

atio

nal P

rior

ity


Oncobiomed Ltda.


Business Partnership77.878.650-3Carlos Roberto Ferrada Valenzuela Pérez Valenzuela 1520, Providencia, Santiago


Eugenio RivasGeneral Assistant(56-2) 236 4716(56-2) 735 3346-- [email protected]


ONCOBIOMED is a biotechnology company that provides highly specialized cell-based therapies to treat cancer diseases. ONCOBIOMED specializes in the development of new technologies, and research and development of biological vaccines for cancer immunotherapy. It develops applied scientific research related to groups of scientists from the Universidad de Chile and participates in research projects in the area of cancer immunotherapy. These biotechnological projects funded by the Scientific and Technological Development Fund (FONDEF) have a prestigious national impact in the international scientific world. As a Chilean biotechnological company, ONCOBIOMED’S activity is focused on product delivery and biotechnological-based therapeutic procedures.

Business Areas


The services ONCOBIOMED provides are comprised of the following areas: - Biological vaccines against malignant melanoma TRIMELVAC-DC;- Clinical research and cellular biotechnology in tumor immunology;- Development of tumor markers for diagnosis- Adjuvant treatments for high-risk cancer patients.ONCOBIOMED’s possible competition is located in USA and Europe. The most important differentiating factor is the final price and the total time of the process. Due to ONCOBIOMED’s location our procedure is delivered faster with an equivalent cost of one third of a comparative therapy in USA or Europe. This has the following advantages: optimal relation between price and quality; no secondary effects for the patient; in addition to the cultural proximity and language being a main advantage for the Latin American market.ONCOBIOMED has a high security laboratory that allows secure processes and production. The company’s vaccine production is up to 50 patients a month.


N°of Employees 3Bachelor degree 2PhD degree 1

Websitewww.oncobiomed.cl



Patagonia Neuroactive Biotechnology


Private76.533.020-3Luis G. AguayoEduardo Rioseco 1172, Concepcion, Chile


Dr. Luis G. AguayoScientific Director(56-41) 295 [email protected]




PATAGONIA NEUROACTIVE began in 1991 with international projects after Dr. Aguayo obtained a doctoral degree in Pharmacology and trained as a Senior Staff Fellow at the National Institute of Health (NIH) in the United States.According to the specific needs for each project, PATAGONIA NEUROACTIVE designs strategic alliances or hires chemists with experience in natural products and synthesis, pharmacologists, veterinarians, pharmacists and other professionals. This multidisciplinary approach gives Patagonia a formidable potential to achieve the fundamental mission of the company.The company’s goal is to investigate natural products derived from plants and other species (mushrooms, marine life, etc.) found in the southern region of South America that has applications in research, medicine and biotechnology. Research focuses on identifying neuroactive products that facilitate the understanding of cellular and molecular mechanisms important in nervous system communication, as well as to discover new neuroactive compounds that can help in neurodegenerative diseases. To accomplish this, PATAGONIA NEUROACTIVE carries out investigations and biotechnological development to determine the interaction between these neuroactive compounds and biological molecules such as receptors and ion channels found in the nervous system.

Website-

Business Areas


PATAGONIA NEUROACTIVE uses cellular and molecular techniques to characterize effects of a diverse group of active compounds including those derived from natural products and others from chemical synthesis. Therefore, PATAGONIA NEUROACTIVE offers the “know how” to identify and characterize sites and mechanisms of action of molecules acting on the nervous system. It has a strategic alliance with the University of Concepcion that allows the wide use of resources to answer the needs for rapid R&D.The company has the capacity to establish interdisciplinary teams to isolate and characterize diverse molecules and determine their actions in the nervous system. In addition, it has identified two new molecules which are of potential use to medical and veterinarian medicine. PATAGONIA NEUROACTIVE is also in the process of patenting a methodology which will be of great advantage to discover new drugs that can treat diseases such as Parkinson’s and Alzheimer’s. In summary, these strengths are not available in the region. PATAGONIA NEUROACTIVE requires an expansion in the area of medicinal chemistry and synthesis as well as in behavioral pharmacology, which together with its cellular and molecular strength will convert the company in a formidable competitor ahead of other companies. The company expects to develop collaborations with other leading, world class, biotech companies to initiate aggressive and focused programs on neurodegeneration and lead compound generation from native plants.

BIOT

ECH,

A N

ATIO

NAL

PRIO

RITY

Biot

ech,

a N

atio

nal P

rior

ity


Plataforma360 Consultores Ltda.


Private Partnership76.713.350-2Blanca VelascoHuerfanos 1022, of. 1207, Santiago


Blanca Velasco VillafañaExecutive Director(56-2) 341 8750--(56-9) 9748 2828


Platform360 is a private consulting, networking and learning company, conformed by professionals and academics with expertise in new enterprises development, incubation and human resources training in the business innovation field. The company’s mission is to generate business articulations and efficient learning for institutions, organizations, companies and entrepreneurs in order to optimize design and sustainability of their business, based on global innovations and creativity, using technological crossroads and practice communities.The professional team has been working on the linkage between the research area and related institutions, programs and tools, and the executive and business area, in order to provide entrepreneurs and their teams with knowledge, learning, networking on innovation and world business practices.Platform360 works with and in the “pipeline” of innovation searching out opportunities in order to add value in productive processes and developing special focus in skill acquisitions for professionals and new researchers/entrepreneurs linked to products and services development from Technological Centers or Enterprises promoting innovation, adaptation or use of proprietary technology. This is reached by training teams in business management and positioning them in global competitiveness parameters, together with generating collaborative learning.Platform360’s network is based on international technological innovation centers and business incubators related to sectors defined by the Chilean Council of Innovation for Competitiveness. In this institutional and business universe, collaboration between intellectual property organizations, angel investors and learning platforms are considered as relevant.Particularly, biotechnology applications and crossroads are a key market for Platform360 and strategic approaches are being developed in this direction. In collaboration with international consulting partners and Chilean Universities, Platform360 is preparing entrepreneurs to develop and manage market-oriented biotechnologies, through a post-degree university program. Furthermore, we are currently working in translating University-based technology projects into commercial applications.

Business Areas


Products and services:- Strategic position analyses- Training in Business models for biotech projects- Consulting in intellectual and industrial property, patent application process and competitiveness intelligence- Analyses with Scene-methods and roadmapping- Coaching oriented to strengthen entrepreneurs commitment and companies success- Maps, networks and angel investors linkages

Competitive advantages of our products/services:- Work style with the entrepreneurs- Specific networks and strategic communication- Professional expertise- Portfolio linkages between scientific and business fields


N°of Employees 3PhD 1Master Degree 2Bachelor -

Websitewww.plataforma360.cl



Quitoquímica Ltda.


Limited Responsibility Society76.112.070-0Galo Cardenas TriviñoGolfo de Arauco 3666, Parque Industrial Coronel, Concepción, Chile


Galo Cardenas TriviñoScientific Advisor(56-41) 285 4103(56-41) 220 3337(56-9) 886 [email protected]


N°of Employees 8Bachelor Degree 4Mechanical Engineer 1Chemistry Technician 2Chemical Engineer 1


QUITOQUÍMICA’s mission is the production of several products friendly with the environment, biodegradable and biocompatible using a biopolymer as support: Chitosan, obtained from crab shells. These types of products can be used in environmental, agriculture and biomedical applications.

Websitewww.quitoquimica.cl

Business Areas


The company specializes in the production of Chitosan and derivatives. Key products are QuitoAgro, QuitoCarbe, Quito- Def, Esferas de QuitoSano. These products differ from the competition in that they are biodegradable and biocompatible. Also, these products do not contaminate the environment or humans. QUITOQUÍMICA produces one half of a ton of product each month.

BIOT

ECH,

A N

ATIO

NAL

PRIO

RITY

Biot

ech,

a N

atio

nal P

rior

ity


Sociedad Punta del Cobre S.A.


Stock Company Inscription N° 036296.561.560-1Sebastián Ríos RivasRancagua 200, Copiapó, Chile


Juan Rivadeneira HurtadoResearch Manager, Planta Biocobre(56-52) 205 810(56-52) 205 811(56-9) 817 [email protected]


PUCOBRE is a mining company active in the acquisition, exploration, development and mining of mineral properties. Over 95% of PUCOBRE’s revenue comes from copper concentrate production at its San José enrichment plant, as well as cathode copper from its Biocopper plant. PUCOBRE has developed technological and scientific research projects and capabilities and is planning to expand its capabilities in this area. PUCOBRE’s strategic objectives are to continue to expand its activities in the mining business with a focus on copper, to materially increase its annual metal production, and increase its profitability, thereby adding value for shareholders.

Business Areas


PUCROBRE produces copper cathodes and concentrate. The company’s expertise is in leaching operation, microbial cultures, bioleaching, and lab resources for bioleaching mineral testing.PUCOBRE produces 10,000 tons of copper cathodes that are exported and 80,000 tons of chalcopyrite concentrate that are sold to the internal copper market.PUCOBRE is looking for new technologies to allow the company to autogenerate the energy requirements to maintain the different copper enrichment operations, new technologies for material and earth movement, water savings and bioremediation.


N°of Employees 374PhD 1Master Degree 4Bachelor Degree 1Geologists 10Engineers 34

Websitewww.pucobre.cl



Schaffeld Kriman & Villegas Ltda.


PrivateRut 78.040.240-7Luis KrimanDPA. Cerda 1180, Suite 403, Concepción,Chile


Luis KrimanExecutive Director(56-41) 230 859(56-41) 230 [email protected]




SK&V Ltda. participates as an associate partner in new endeavors. SK&V is also assisting foreign companies in industrial joint ventures, representations and consulting.

Websitewww.skv.tripod.cl

Business Areas


The companies main products are consulting, research and development in biotechnology businesses

BIOT

ECH,

A N

ATIO

NAL

PRIO

RITY

Biot

ech,

a N

atio

nal P

rior

ity


Tauern S.A.


Private Company96.557.540-5Johann Janko MoragaLos Molles 0899, Santiago


Johann Janko MoragaGeneral Manager(56-2) 622 4844/4845(56-2) 622 [email protected]


TAUERN is company with more than 18 years in the market, to solve problems in four main areas: The packing industry, the agricultural sector, the veterinarian sector and the food industry.

Business Areas


TAUERN main products are:Packing industry: Absorber pads for chicken and fish packing. Absorber carpets for air transportation of goods with leakage risk. Pads for the fruit export industry. Ice substitutes (gel packs) for packing. Those products are developed by TAUERN and are accepted by the most important factories in Chile. The products have an excellent efficiency / price correlation. Veterinary area: Nutra Silo inoculants for ensilage of animal food (based on lactobacillus). The features of Nutra Silo are its liquid form for easy application and its classification as an organic certified product by IMO. Agriculture: FRUITSAN organic fungicide, classified by IMO, with excellent results in field applications and for conservation after harvest particularly for grapes, berries and other fruits to prevent Botritis Spp. TAUERN is interested in entering the market in other countries with this fungicide, especially in the USA and Europe.Other products in this area are: STOCKOSORB, super absorber polymer, formulated in Germany to increase water absorption in soil particularly for forestry and agriculture. Amino acids from Spain (INAGROSA). Food industry: TAUERN’s first research development was TAUERN-Lac, a food preserver with Lactobacillus also produced in conjunction with the Economic Development Agency (as a research project).


N°of Employees 23Bachelor Degree 10Other 13

Websitewww.tauern.cl



Internacional Trade Consultants S.A.


Private company77.409.410-5Sergio KalmBarros Errázuriz 1954, # 204, Providencia, Santiago


Verónica MedinaChief Operating Officer(56-2) 244 2435(56-2) 244 [email protected]




TradeChile began activities in 1995 as a Chilean consulting firm dedicated to facilitating investment and trade to and from Chile and to providing service of superior quality. TradeChile offers a set of integrated business consulting services and market intelligence. These services are aimed at facilitating the activities undertaken by trade and investment promotion entities, as well as export and investment promotion efforts initiated by states, provinces, business associations, individual companies, etc. TradeChile is the official representative of the Commonwealth of Pennsylvania, USA and the Provinces of Ontario, Manitoba, Saskatchewan and PEI, Canada.TradeChile has extensive experience in the Chilean biotechnology sector, including participation in BIO2005, BIO2006 and BIO2007, organizing meetings for Chilean companies and governmental officials that analyze business and investment opportunities, installation of a Canadian advanced biotechnology lab in Santiago, and executing a comprehensive study of the market, among others.

Websitewww.tradechile.cl

Business Areas


The service package is defined in conjunction with each client. Services usually include: - Market reports including identification of strategic partners - Investment attraction- Business sector research - Periodical economic outlooks- Representation and assistance in trade shows and fairs- Arrangements for trade missions- Scheduling of “matchmaking” agendas for companies and official delegates- Videoconferencing- Local “Branch Office Showroom”- Monitoring market opportunities, including participating in government procurement bids- Business rounds / seminars at the geographical location of the client- Monthly and annual reports and activities and results- Legal and financial services TradeChile has extensive experience in business facilitation endeavors in the local market and is supported by a broad network of partners and contacts in the USA and Canada. The company’s accumulated experience makes it unique as we have provided consulting services to both national and international clients for the last 10 years.

BIOT

ECH,

A N

ATIO

NAL

PRIO

RITY

Biot

ech,

a N

atio

nal P

rior

ity


Valtek Diagnostics


Private79.568.850-1Rodolfo Valdés Echenique Avenida Marathon 1943, Ñuñoa, Santiago


Rodolfo Valdés EcheniqueGeneral Manager(56-2) 654 1100(56-2) 654 1199(56-9) 220 [email protected]


VALTEK, with more than 20 years in the market, has combined the best raw materials, highly qualified personnel, and strict quality control, in developing a complete line of liquid stable and powdered reagents to provide accuracy, precision and speed in your laboratory tests. Its reagents for clinical diagnosis have been formulated according to the most modern methods.Since December 2002, the quality management of VALTEK is certified according to ISO 9001:2000 for it’s processes of Research, Development, Manufacture, Production, Sales and Distribution of Diagnostic Kits and Reagents, (SGS, Société Générale de Surveillance, certificate number MX03/0085; accredited by Instituto Nacional de Normalización – Chile and UKAS – England).

Business Areas


VALTEK offers quality, technology and cost efficient solutions for clinical chemistry. At VALTEK, research and development is a constant effort. A highly qualified team with extensive experience in biotechnology is the fundamental basis of the company’s effort to give clients the best products and the best technology. VALTEK’s quality standards are applied to all the productive areas and processes, from raw materials used to the end product. VALTEK personnel, trained in the philosophy of Total Quality and backed by the most modern equipment available, enable us to offer a product that is controlled from the very start, thus ensuring quality throughout time, as well as the least possible batch-to-batch variation.The company’s main products are:- Metabolites- Enzymes- Latex serology- Control Sera and calibrators- Pregnacy tests- Blood Grouping Reagents- Antibiogram


N°of Employees 35Bachelor Degree 9Administratives 9Sales Department 7

Websitewww.valtekdiagnostics.com



Voz Chile Ltda.


Private Corporation76.275.640Carla Cristina Avila RamirezEdificio Congreso, Sótero del Río 508, Office 836, Santiago


Carla AvilaCEO(56-2) 569 0102(56-2) 662 1437(56-9) 364 [email protected]




VOZ CHILE is a multidisciplinary consulting firm and commercial agent whose aim is to contribute to the success of its clients’ internationalization projects. It specializes in technology integration and transfer, as well as in investment promotion, in the fields of environmental and bio-technologies.As a subsidiary of VOZ International inc. of Canada, VOZ Chile Ltda keeps an active presence on three continents: North America (Canada), Europe (Spain) and South America (Chile). Its experience has allowed VOZ Chile to develop the necessary tools and resources to identify and take advantage of business opportunities from their very origin, and to help bring the projects to fruition with minimum costs and risks.VOZ Chile has developed a project-based methodology that provides the necessary tools to meet the requirements of the international commercial cycle. VOZ Chile is the only company in Chile that offers small- and medium-sized businesses a complete integrated program of services from the pre-commercial phase to the operational phase of commercial ventures.

Websitewww.vozinternational.com

Business Areas


VOZ Chile offers its Chilean clients from the environmental, energy and agri-food sector, and technology-based firms serving these sectors, a series of services, named PRObiotec Plan. It is designed to help the company build and implement a strategic internationalization plan, which will cover all aspects of the process that leads from the first project idea to its final completion. Through the PRObiotec Plan, all technical, financial and strategic aspects of the project will be dealt with in an integrated process. VOZ Chile has the capacity to master all the necessary tools and resources needed to develop and implement such a plan in the complex setting of an international project. These tools and resources include:- A multi-disciplinary team of associated experts- A wide network of international partners- A powerful methodology for retrieving and analyzing strategic information- A proven capability to obtain public and private financing


Clin

ical

Tria

ls M

arke

tCl

inic

al T

rial

s M

arke

t

77

Clinical Trials Market



Chile encourages foreign R&D investment and is particularly interested in investments targeted at developing the pharmaceutical clinical research. For this purpose the Chilean Government is developing an operational model designed to close the gap when compared with the best Clinical Trial markets in the world.

In line with this objective, the Ministry of Health is putting in place all the elements for a world-class regulatory environment including best-in-class Ethical Committee Guidelines.

All these efforts are the reflection of the commitment of Chile to become a world-class biopharmaceutical R&D location.

In this regard CORFO has developed several financial incentives designed to attract Clinical Research initiatives to the country that are available for your review (p. 119).

We invite you to assess them and Chile as a preferred location for conducting your research. Our country offers reliable, competitive and highly skilled researchers in a stable and safe business environment for your company and a high quality of life for your employees.

Clinical Trials Market

Clin

ical

Tria

ls M

arke

tCl

inic

al T

rial

s M

arke

t


Estimated Size of Market

The industry presented the following results during 2005:

14 of the major multinational pharmaceutical companies invested over US$16 million in Clinical Research in Chile (6,2 % more than 2004)

197 clinical studies have been carried out (19 % more than 2003)*

300 research sites along the country

208 trained and qualified clinical investigators

5707 patients enrolled

Clinical Research Organizations

Bayer Schering Pharma

Biohealth LLC Chile

Center for Clinical Research and Pharmacological Studies (CICEF)

Clinical Research Unit, Sanofi-Aventis Chile

Clinical Trials Center of the University of Concepción

Dr. Mix C.R.O. Ltda.

Latin American CRO MMATISS

Latin American Technological Institute Chile Limitada

Los Lagos Clinical Trials (LLCT)

MDS Pharma Services (MDS PS)

Organon Chile Limitada – Global Clinical Monitoring Organization

Patricio Valdés & Co Ltda.

Pfizer Inc

Roche Chile Limited

* November 2006, www.clinicaltrials.gov



Bayer Schering Pharma

Headquarters

Years of Experience

Regional Offices

Müllerstr. 178, 13353, Berlin, Germany.

More than 100 years of experience in clinical studies.

Chile, Argentina, Bolivia, Uruguay, Paraguay; Brazil, Colombia, Ecuador,

México, Peru, Venezuela.

Contact in Chile

Job Title

Address

Telephone/fax

Dr. Marisol Bruzzone

Head of Medical Affairs

Carlos Fernández 260, San Joaquín,

Santiago.

(56-2) 5208323 - (56-2) 5543484

Email

[email protected]

Websitewww.bayer.cl

Company Description

Research-based pharmaceutical company, with core competences in the fields of health care,

nutrition and high-tech materials.

Areas of Expertise

- Diagnostic Imaging (contrast media, magnetic resonance imaging)

- Hematology and Cardiology (hemophilia, peripheral arterial occlusive disease, pulmonary arterial

hypertension, blood-saving for open heart surgery, thromboembolism prevention and treatment)

- Oncology (hematological tumors and solid tumors)

- Primary Care (cardiovascular disease prevention, hypertension, coronary heart disease, anti-

infective, metabolic disorders)

- Men’s Health (hormones and erectile dysfunction)

- Specialized Therapeutics (multiple sclerosis, eye disease)

- Woman’s Healthcare (hormonal contraception, menopause management, gynecological therapy)

Services

At Bayer Schering Pharma Chile we have the insourced capability to conduct international clinical

studies.

Clin

ical

Tria

ls M

arke

tCl

inic

al T

rial

s M

arke

t


Headquarters

Years of Experience

Regional Offices

201 S. Biscayne Boulevard. Miami Center Suite 1350.

Miami, Florida 33131. USA

2 years as a company and 10 in bioequivalence studies (BE/BD).

Chile, Miami

Contact in Chile

Job Title

Address

Telephone/fax

Jose Frugone

Executive Director

Rosal 325, Suite 1. Santiago Centro. Chile

(56 2) 3505 370 - (56 9) 9 884 6725

Email

[email protected]

Websitewww.biohealth-crc.com

Company Description

Biohealth is specialized in providing support for the pharmaceutical industry as a CRO (Clinical

Research Organization).

Areas of Expertise

BE/BD, Clinical trials phase III and IV in multicenter studies.

Services

- Clinical trials phase III and IV,

- Bioequivalence studies

- Pharmacokinetic studies

- Pharmacodynamic studies

- Dose-response studies.

Biohealth LLC Chile



HeadquartersYears of ExperienceRegional Offices

Faculty of Medicine, University of Chile. Santiago, Chile

2 years

Chile

Contact in ChileJob TitleAddress

Telephone/fax

Pablo Caviedes, M.D., Ph.D.

Director

Independencia 1027, Santiago

Tel: (56-2) 9786145 - Fax: (56-2) 7355855

[email protected]

pcaviede @med.uchile.cl

Websitewww.cicef.cl

Company Description

CICEF is devoted to clinical and preclinical pharmacological research. CICEF specialists have a recognized track

record in international, multicenter, clinical trials, especially in pediatrics. They have successfully coordinated

networking collaborations with 25 outpatient clinics, 3 pediatric emergency hospitals, 12 neonatology units, 3

large pediatric hospitals, and 12 pediatric inpatient services in Santiago and provinces.

CICEF has access to a large clinical base (more than 1500 hospital beds and more that 500,000 children between

0 and 18 years of age).

The center is harbored in the Faculty of Medicine, University of Chile, and its members are faculty professors

of the Biomedical Sciences Institute in this Faculty. The platform provides expertise in clinical trials, and strong

support from well established basic and preclinical laboratories, all of which constitute an organization of highly

recognized leadership.

The center handles clinical trials in Phase II and III, which are carried out in collaboration with a large network of

hospitals and outpatient centers localized in the country, following GMP regulations.

Areas of expertise include epidemiological and disease impact studies, and studies evaluating efficacy and safety

of diverse drugs including antimicrobials and vaccines.

Areas of Expertise

- Pediatrics

- Neonatology

- Pediatric and Adult Infectious Diseases

- Antimicrobials

- Infections in the immunocompromised host

- Cardiovascular diseases

- Neurological disorders

Services

CICEF offers high quality and ethical standards and an adequate administration. Studies to be conducted

are evaluated by The Ethics Commission for Human Research of the University of Chile School of

Medicine and by Ethics Committees of the corresponding areas of health care within the National Health

Service System.

- Direction, organization, coordination and

execution of clinical trials Phase II – IV

- Implementation of Phase I studies

- Bioequivalence studies

- In-vivo and in-vitro models for evaluation of

activity of antimicrobial compounds

- Clinical trials design

- GCP and regulatory training for physician

investigators and collaborating professionals.

Centre for Clinical Research and Pharmacological Studies (CICEF)

Clin

ical

Tria

ls M

arke

tCl

inic

al T

rial

s M

arke

t



Sanofi-Aventis Chile, Santiago, Chile

18 years in Clinical/Medical Research

More than 25 R&D Centers on 3 continents

Contact in ChileJob TitleAddressTelephone/fax

Emma Venezian, Md

Director Clinical Research Unit,

Sanofi-Aventis Chile

Lyon 222, Office 604,

Providencia, Santiago, Chile

(56-2) 330 6682 - (56-2) 232 0756

Company Description

R & D Global Pharmaceutical Company

Areas of Expertise

All Therapeutic Areas

Services

Clinical Research

Clinical Research Unit, Sanofi-Aventis Chile

EmailEmma.Venezian@Sanofi-Aventis.

Com

Websitehttp://en.sanofi-aventis.com/



Headquarters

Years of Experience

Regional Offices

High Complexity Ambulatory Center, Las Higueras Hospital, Talcahuano

1year

Chile

Contact in Chile

Job Title

Address

Telephone/fax

Francisco Albornoz, MD, MSCI

Director

Alto Horno 777, Talcahuano

(56-41) 250 1481

Email

[email protected]

Websitewww.udec.cl

Company Description

A Clinical Trial Center for Phase II and III for drugs and devices in medicine

Areas of Expertise

Cardiovascular, Neurology, Mental diseases, Cancer

Services

Clinical Trials Phases II and III

Clinical Trials Center of the University of Concepción

Clin

ical

Tria

ls M

arke

tCl

inic

al T

rial

s M

arke

t



Javiera Carrera Norte # 105 , La Reina , Santiago , Chile17 yearsAffiliates partners in Chile, Peru, Ecuador, Argentina and Uruguay


Dr. Harold MixMedical DirectorJaviera Carrera Norte # 105, La Reina, Santiago, Chile(56-2) 325 5042

[email protected]

Company Description

Dr. Mix, MD, specialist in Otorhinolaryngology and Clinical Research, certified by the Postgraduate School of the Faculty of Medicine and Faculty of Chemistry and Pharmacy, University of Chile. Started clinical research and marketing support activities in 1990, as Medical Director of local subsidiaries of international pharmaceutical companies (Boehringer Ingelheim and Pharmacia Upjohn) and as Consultant in Clinical Research, providing services as regional coordinator in Latin America for Takeda Global Research & Development Center. Other companies and CROs like IVAX Pharmaceuticals, TEBA, Kos Pharmaceuticals, Servier, CAC Oncology and Kendle are among his customers. In 2003 set up a local CRO called IC-CHILE Ltda., affiliated to a regional Latin American CRO called IC-Research (International Clinical Research). This company merger with KENDLE last year. Additionally Dr. Mix has organized and directed more than 20 workshops on Clinical Research, with the participation and certification of more than 500 participants (investigators, study coordinators and Ethic Committee members). Dr. Mix is the Director and Professor of the Postgraduate Diploma Course on Clinical Research at the Faculty of Chemistry and Pharmacy, University of Chile. More than 50 postgraduate students obtained their Diploma and also the title of Clinical Research Associate, after 2 semesters of studies, last year. In 2005, Dr. Mix set up his own CRO company, providing services initially as Consultant on Research & Clinical Operations but nowadays also as SMO/CRO. The number of employees depends on demand, because most CRAs are freelanced home-based employees. Therefore operational costs remains low and it allows offering a competitive alternative to carry out clinical trials in Chile and neighbor countries.

Areas of Expertise

• Diabetes Mellitus – Dyslipidemia – Arterial Hypertension – Atherosclerosis –- Heart Failure – Myocardial Infarction – Intermittent Claudication - Thrombosis

• Osteoarthritis - Rheumatoid Arthritis – Shoulder pain – Lumbosciatica – Ankle Sprain – Ankylosing Spondylitis – Psoriasis Arthritis -

• Asthma – C.O.P.D. – Pneumonia – U.R.T.I. – Sinusitis – Otitis Media – Tonsillitis

• Diabetic neuropathy - Neuropathy pain - Cancer pain – Dental pain

• Sleep disorders – Schizophrenia – Depression – Psychotic Disorders

• G.E.R.D. – Colorectal Familiar and Sporadic Adenomatous Polyps – Constipation

• H.I.V. - Skin infections – M.R.S.A. infections – Sepsis – Febrile Neutropenia

• Overactive bladder and Nicturia – Erectile Dysfunction – Prostatic Cancer – U.T.I.

• Contraception – Dysmenorrhea – Endometriosis – Breast Cancer –

• Glaucoma - Conjunctivitis

Services

- Phase II-IV clinical development - Project management and planning - Clinical trials management - Feasibility and site selection- National and regional regulatory affairs services- Representation at MOH – ISP – IEC - IRBs- Bilingual personnel - Bilingual Investigator Meetings- Bilingual Investigators and site teams - Site contract management and payments

- Regulatory and medical consulting - Regulatory document collection and submission- Importation / exportation activities- Drug depot services- Training of staff personal and study sites- Accelerated patient recruitment - Monitoring activities- Safety Officers Activities- Local reporting of safety issues

Dr. Mix C.R.O. Ltda.

Dr. Mix has carried out more than 60 clinical trials, Phase II-III, with more than 2,500 patients enrolled, in almost all major medical fields:



Latin American CRO MMATISS

Headquarters

Years of Experience

Regional Offices

Mexico

11 years

Chile, Brazil, Argentina

Contact in Chile

Job Title

Address

Telephone/fax

Marcos Valenzuela Lopez (Chile Office), Hector De

Lille (Headquarters office)

Manager Chile

Guardia Vieja 181 Suite 203, Providencia,

Santiago, Chile.

(56-2) 9748 1472

Company DescriptionContract Research Organization.

Areas of Expertise

- Rheumatoid Arthritis and Osteoarthritis - Traumatology - Depression - Asthma - Breast, Renal, Hepatocellular, Lung and Skin Cancer - Cephalea - Muscular and skeletal pain - Post surgery pain - Gastroenterology - Hypertension - Infectious Diseases - Pneumonia - Ear Infection- Diabetes Mellitus - Endocrine - Ethical Products and OTC’s- Food Substitutes

Services

- Strategic consulting- Clinical research & development • Phase I -IV international, multi-center studies - Regulatory affairs • Related to clinical trials • Pre & Post Marketing Authorization grant

[email protected]; [email protected]; [email protected]

Websitewww.mmatiss.com

Clin

ical

Tria

ls M

arke

tCl

inic

al T

rial

s M

arke

t


Headquarters

Years of Experience

Regional Offices

México D.F.

More than eight years for experience.

Chile, Mexico, Argentina, Brazil, Peru, Guatemala

Contact in Chile

Job Title

Address

Telephone/fax

Marcos Valenzuela López. In México

Biol. Leticia Pulido

Doctor

Guardia Vieja 181-203, Providencia,

Santiago, Chile

(56-9) 748 1472

[email protected]

[email protected]

Websitewww.lamtechinstitute.com

Company Description

LamTech provides training for clinical research professionals based in international standards

and offers pharmaceutical biotechnology companies and CROs, a better way to quickly resource

professionals with expertise on Investigation fields

Areas of Expertise

Clinical Research

Services

Training and human resources with expertise on Investigation field

Latin American Technological Institute Chile Limitada



Headquarters

Years of ExperienceRegional Offices

Medicine and Veterinary Sciences Faculties, Universidad Austral de Chile, Valdivia, Chile.15 yearsChile


Juan Hancke, DVM, PhDDirectorCampus Isla Teja, Valdivia(56-63) 221 216 - (56-63) 293 187

[email protected]@uach.clWebsitewww.uach.cl

Company Description

Academic and Service Center, dedicated to pre clinical and clinical pharmacological research.Specialists enrolled in LLCT project, have a recognized track record in national and international, multicentered clinical trials, especially in pediatrics and internal medicine. Working in connection with well known international CRO with headquarters in Chile and also independently, they have successfully coordinated networking collaborations with outpatient clinics, pediatric and adult emergency hospitals, neonatology units, large pediatric and adult hospitals, and non surgical adult and pediatric inpatient wards, in Santiago metropolitan area and in the provinces of Chile as well.LLCT has access to a large clinical base of 30 major hospitals in Chile (more than 3500 hospital adult and pediatric beds).The center is harbored in the University Austral de Chile, and its members are professors of the Faculties of Medicine, Veterinary Sciences, Science, Philosophy (Bioethics), the School of Law, and the Institute of Biostatistics. This platform provides expertise in clinical trials, and strong support from well established basic and preclinical laboratories, all of which constitute a well recognized performance organization.The center handles clinical trials, mainly in Phase I and II, participating also in Phase III, which are carried out in collaboration with a network of hospitals and outpatient centers localized in the country and abroad, following GMP regulations.Staff expertise areas, have been related to the search of new pharmaceutical products, design of basic, preclinical and clinical research protocols, which involve studies evaluating efficacy and safety of diverse drugs. In addition, recent experience includes national and international licensing and due diligences for patent claims, technological transfer and industrial development for nutraceuticals, natural compounds, antileucotriens, anti-inflammatory, immunomodulators, oral hypoglucemics.

Areas of Expertise

- Oncology- Internal Medicine- Pediatrics

- Inflammation- Rheumatology

- Metabolic and Cardiovascular diseases- Neurological disorders

Services

Los Lagos Clinical Trials (LLCT)

LLCT offers high quality scientific, clinical and ethical standards with an adequate administration, in areas such as:- Pharmacological studies: - In-vivo and in-vitro models for evaluation of

activity of natural compounds.- Design and direction of clinical trials.- Organization, coordination and execution of

clinical trials Phase I – II.- GCP and regulatory training for physician

investigators and collaborating professionals.

Studies to be conducted are evaluated and supervised by The Ethics Commission for Human Research of the University, School of Medicine and by the Ethics Committees of the corresponding areas of the Regional Public Health Services, within the National Health Service Centers Network.

Clin

ical

Tria

ls M

arke

tCl

inic

al T

rial

s M

arke

t



King of Prussia, PA USA

More than35 years (6 years in Latin America)

Chile, Argentina, Brazil (opening soon), Mexico and Peru.

Contact in ChileJob TitleAddress

Telephone/fax

Brice Bonvalet

Regional Project Leader

Av. Vitacura 2808, Of.502 - Las Condes,

Santiago

(56-2) 431 0560 - (56-2) 431 0549

Email [email protected]

Websitewww.mdsps.com

Company Description

As a Contract Research Organization (CRO), our purpose is a simple one to make a distinctive contribution

to the health and well-being of people around the world. We work in partnership with our customers to

increase their effectiveness, precision and productivity, helping them to create better outcomes in the

treatment of disease. Our reputation has been built on more than 35 years of reliability, superior products

and services and collaborative relationships. From our inception, we have continued to be driven by our core

values: mutual trust, respect for people, integrity, and commitment to excellence.

Areas of Expertise

MDS PS is recognized for therapeutic expertise and experience that cover many major therapeutic

areas. Our project teams and partners in Latin America are experienced in executing clinical trials in the

following therapeutic areas: Oncology, Cardiovascular, Metabolic Disorders, CNS, Vaccines, Respiratory,

Allergy, Infectious Diseases

Services

Core services offered by Global Clinical Development (Phase II to IV) are:

- Feasibility Research

- Regulatory Affairs

- Investigator recruitment and site selection

- Patient Recruitment

- Project Management and Clinical Monitoring

- Medical Affairs and Safety Management

- Central Labs (affiliate labs located in Argentina, Brazil and Mexico)

- Data Management (including EDC)

- Biostatistics

- Medical and Scientific Writing

- Quality Assurance

MDS Pharma Services (MDSW PS)



Organon Chile Limitada-Global Clinical Monitoring

Headquarters

Years of Experience

Regional Offices

The Netherlands

9 years in clinical research

Chile, Brazil

Contact in Chile

Job Title

Address

Telephone/fax

Carmen Gloria Moyano

Clinical Research Manager

M. Sánchez Fontecilla 310, 8th floor –

Las Condes - Santiago

(56 2) 350 0151 - (56 2) 350 0162

Company Description

Renowned global biopharmaceutical company, committed to improving the health and quality of

human life.

Our products are distributed in over 100 countries, of which more than 50 have an Organon subsidiary.

Organon is the human health care business unit of Akzo Nobel.

Areas of Expertise

Organon seeks to leverage its position as a leading biopharmaceutical company in each of our core

therapeutic fields: fertility, gynecology and selected areas of anesthesia. In addition, we have extensive

experience in neuroscience, and we conduct research in immunology and oncology.

Services

GCM is an internal organization for monitoring clinical trials for Organon

[email protected]

Websitewww.organon.cl

Clin

ical

Tria

ls M

arke

tCl

inic

al T

rial

s M

arke

t


Patricio Valdés y Compañía Limitada

Headquarters

Years of Experience

Regional Offices

Universidad de La Frontera, Temuco, Chile

15 years

Chile

Contact in Chile

Job Title

Address

Telephone/fax

Patricio Valdés

Physician PD

Manuel Bulnes 815 Suite 507, Temuco

(56-45) 234 326

Company Description

Research in Clinical Trials

Areas of Expertise

- Contraception- Reproductive Medicine- Infertility- Endometriosis- Breastfeeding

Services

Clinical Research and Clinical Trials

[email protected]

Websitewww.ciges.cl




New York, NY (USA)

Founded on 1849, over 100 years of experience in research.

Chile, Argentina, Brazil, Peru, Colombia, Ecuador, México, Venezuela


María Teresa Silva

Clinical Research Manager

Las Américas 173, Cerrillos, Santiago

(56-2) 241 2186 - (56-2) 241 2191

Company Description

Pfizer Inc is the world’s largest privately funded biomedical research organization.

Founded in 1849, is dedicated to better health and greater access to healthcare for people and their

valued animals. Our purpose is helping people live longer, healthier, happier lives. Our route to that

purpose is through discovering and developing bre akthrough medicines; providing information on

prevention, wellness, and treatment; consistent high-quality manufacturing of medicines, consumer

products; and global leadership in corporate responsibility.

Every day we help 38 million patients, employ more than 100,000 colleagues, utilize the skills of more

than 12,000 medical researchers, and work in partnership with governments, individuals, and other

payers for healthcare to treat and prevent illnesses adding both years to life, and life to years

Areas of Expertise

Pfizer’s search for new treatments spans hundreds of research projects across 11 therapeutic areas. Our

scientists, clinicians, technicians, and other professionals employ state-of-the-art tools ranging from

robotic high-throughput screening (a method pioneered by Pfizer) to sophisticated genomic studies, to

deliver a steady stream of innovative new products that enhance human and animal health.

Pfizer conducts research and development across 11 therapeutic areas:

Pfizer Inc

[email protected]

Websitehttp://www.pfizer.com

- Allergy & Respiratory

- Cardiovascular, Metabolic & Endocrine

Diseases

- Central Nervous System Disorders

- Dermatology

- Gastrointestinal Diseases

- Infectious Diseases

- Inflammation

- Oncology

- phthalmology

- Pain

- Sexual Health & Urogenital Disorders

Services

Pfizer Chile Clinical Research Unit has over 30 years of experience in monitoring multicentric

international trials.

Clin

ical

Tria

ls M

arke

tCl

inic

al T

rial

s M

arke

t



Basel - Switzerland

35 years of presence in Chile, more than 100 over the world.

Chile, Argentina, Brazil, Colombia, Costa Rica, Ecuador, El Salvador, Guatemala,

Honduras.


Dr. Emilio Sánchez Q.

Medical Director

Quilin Avenue # 3279, Macul, Santiago.

(56–2) 441 32 00 - (56–2) 221 0148

Company Description

Roche is a leading healthcare company with a uniquely broad spectrum of innovative solutions. For

more than 100 years, we have been active in the discovery, development, manufacture and marketing

of novel healthcare solutions. Our products and services address prevention, diagnosis and treatment

of diseases, thus enhancing well-being and quality of life.

Areas of Expertise

Biotechnology, Oncology, Cardiovascular, Central Nervous System, Dermatology, Infectious Diseases,

Inflammatory and autoimmune diseases, Metabolic Disorders, Transplantation, Diagnostics tests

Services

Roche’s Diagnostics Division, offers a wide range of services in all fields of medical testing. We have

a unique capacity in people and technology to provide innovative, cost-effective, timely and reliable

solutions in biomedical research, laboratory diagnostics and patient self-monitoring.

Roche Chile Limited

Email-

Websitewww.roche.cl


TECH

NOLO

GY T

RANS

FER

CENT

ERS

AND

BUSI

NESS

INCU

BATO

RS

Tech

nolo

gy T

rans

fer

Cent

ers

and

Busi

ness

Incu

bato

rs

95

Technology Transfer Centers and Business Incubators



There are ten world-class Technology Transfer Centers in Chile that are available for outsourcing R&D initiatives related to biotechnology and life sciences. They are managed by teams of PhD scientists trained in some of the most reputed universities of the world.

These centers strive to enhance industry interactions by combining the resources of experts in the fields of biotechnology, pharmacy, engineering, architecture, veterinary medicine, sciences and agriculture.

These multidisciplinary Centers offer a unique source to improve research, productivity, and graduate education.

Technology Transfer Centers

Biotechnology Center “Dr. Daniel Alkalay Lowit” CB-DAL

Biotechnology Center of the University of Concepción CBUdeC

Biotechnology Center Profesor Alberto Ruiz

Center of Biotechnology and Molecular Biology CBBM

Center for Advanced Research in Fundamental and Applied Biomedicine CIAB

Center for Biochemical Engineering and Biotechnology CIBYB

Center for Clinical Research and Pharmacological Studies CICEF

Institute of Biomedical Sciences ICBM

Núcleo Biotecnología Curauma

Salvador Hospital Rheumatology Center

Centers Profiles

TECH

NOLO

GY T

RANS

FER

CENT

ERS

AND

BUSI

NESS

INCU

BATO

RS

Tech

nolo

gy T

rans

fer

Cent

ers

and

Busi

ness

Incu

bato

rs


Biotechnology Center “Dr. Daniel Alkalay Lowit” CB-DAL


University Federico Santa María81.668.700 – 4José Rodríguez PérezAv. España 1680, Valparaiso, Chile


Manuel E. YoungDirector(56-32) 265 4730(56-32) 265 [email protected]


N°of Employees 4PhD 2Master degree 2Bachelor Degree -


The Center for Biotechnology “Dr. Daniel Akalay Lowitt” CB-DAL, is an applied research unit belonging to the University Federico Santa Maria. It was created on January 2000, with the purpose of performing industrially oriented research in the fields of Plant Biotechnology, Biosensors and Bioreactors. Main source of founding comes from public grants from the most important Chilean founding agencies.The operation is based on a small number of highly qualified full time research personnel that operate in the Valparaiso Campus. Our modern laboratory facilities are oriented toward genetic engineering, genomics, tissue culture, complemented with an analytical laboratory that includes GC-MS, HPLC, PCR, real time PCR. To complement the Center’s operations CB-DAL generates partnership with leading research institutions, local and abroad, in the co-execution of projects or in creating consortiums together with private corporations.

Websitewww.biotec.ufsm.cl

Business Areas


The main services that the Center provides are: - Microarray service: the CB-DAL is equipped with the instruments to provide the service for microarray’s

preparation, hybridization and data processing.- Technological platform for transgenic plant production.- Technological platform for plant micropropagation.- Technological platform for microbial biosensor development.- Custom made transgenic, micropropagation and biosensors.- Metabolite analysis through GC-MS, HPLC- Molecular analysis through PCR, real time PCRCB-DAL’s microarrays can be prepared in membranes or slides.



Biotechnology Center of the University of Concepción CBUdeC


University of Concepción81.494.400-KSergio Lavanchy Merino----


Jaime Rodríguez GutiérrezDirector (56-41) 220 3850(56-41) 220 7310(56-9) 8249 [email protected]




The Biotechnology Center was created on December 2002. Since then, 21 biotech research projects have been consolidated with an investment that grows up to 10 million dollars.CBUdeC has 3.000 m2 of world class equipped labs and multidisciplinary work teams, strongly linked with international centers of world excellence. The most important development areas are Forestry, Aquaculture, Biofilms, Biofuels, and the first Biosafety Diploma taught in the world, that has being developed jointly with UNIDO.

Websitewww.centrobiotecnologia.cl

Business Areas


The Biotechnology Center has the best scientist staff, fully qualified, with complete specialization degrees, highly motivated and capable to deal with new research programs, development and innovation in order to create biotechnological businesses.CBUdeC has consolidated research lines in the following areas:- Production of biolignin.- Biofuels- Biocontrol- Aquaculture - Biofilms to control the pathogens in fish.- Environmental Microbiology- Use of synthetic gels to micro propagation.- Forest Biotechnology- Biosafety

TECH

NOLO

GY T

RANS

FER

CENT

ERS

AND

BUSI

NESS

INCU

BATO

RS

Tech

nolo

gy T

rans

fer

Cent

ers

and

Busi

ness

Incu

bato

rs


Biotechnology Center Profesor Alberto RuizOwnership and StructureRegistration NumberLegal RepresentativePostal Address

University Católica del Norte-Cecilia DemergassoAvda. Angamos 0610, Antofagasta, Chile


Cecilia DemergassoTechnical Manager(56-55) 355 622(56-55) 355 [email protected]


N°of Employees 8


Biotechnology Center Prof. Alberto Ruiz, founded in 2002, is a spin-off company composed by a group of researchers from the University Católica del Norte (UCN), Antofagasta, Chile.The Center’s main activities are research, developing, innovation, monitoring services, training and professional assistance in biotechnology and geomicrobiology.It develops applied biotechnological solutions to meet the specific requirements of innovation and control in mining production processes of the Region enterprises.

Websitewww.lmt.cl

Business Areas


The Center’s services portfolio includes evaluations and characterizations of microbial communities; bioleaching tests; search of exploitable biological material, developing and innovation in biotechnological processes. Using modern biological techniques the Center has developed and transferred new methods to the mining-production through advanced biotechnological services. Developments include monitoring techniques and selective cultures for industrial bacterial leaching processes that improve and optimize bioheap or dump leaching performance.The Center’s services are characterized by:- Accurate, low time answering and customized services on the field, avoiding changes in dynamic

bacterial communities.- Certified by the Chilean standards INN (NCh-ISO17025).- Pioneer work in multidisciplinary national and international research groups in the study of extreme

habitats of the Atacama Desert to determine biogeochemical occurrences as potential exploitable biological material.

- Wide collaboration and relationships with border foreign research institutions


100

Center of Biotechnology and Molecular Biology CBBM


University of Antofagasta.70.791.800-4Pedro Córdova MenaUniversidad de Antofagasta, FAREMAR, Casilla 170, Antofagasta, Chile


Chavez-Crooker PamelaDirector(56-55) 637 868(56-55) 637 804(56-9) 895 [email protected]


N°of Employees 1Bachelor degree 7 Master degree 4Phd degree 2Secretary 1Research Assistant 5


CBBM was created to improve biotechnology research and academic excellence at Universidad de Antofagasta, under the support of the Education Ministry through MECESUP Granting. CBBM’s mission is:1) To conduct research in molecular biology of marine and freshwater microorganisms, aquaculture,

industrial processes, marine pollution and bioremediation. 2) Based on this research, improve methods and processes; develop industrial applications of microbial

products and implement new techniques for environmental cleanup.

Website-

Business Areas


CBBM main products are: 1. Extremophiles for biomining development 2. Extremophiles for bioremediation (arsenic and lead)3. Pectenplus, a new product to induce scallop maturation using clean technology4. Bioproducts for scallop larvae settlement induction 5. Identification and diagnosis of bulking and foaming causing microorganismsCBBM products have been designed and developed in our labs and are based on native microorganisms from the Atacama Dessert. These microorganisms have great advantages on stability and activity under denaturing conditions. CBBM products are highly effective and reliable. Unique properties give the products a highly competitive edge. CBBM labs have the required equipment to develop work on extreme microbiology, proteomics and genomics. Areas for protein purification, electrophoresis, and biochemical characterization are well established.CBBM’s expertise is the purification and characterization of proteins/bioactive compounds from marine bacteria and invertebrates. Genes and protein expression are also studied. Also, the Center’s interest is to develop microorganisms or bioactive compounds at lab scale and pilot level. The industrial level is developed together with local companies.

/ PARTNERING BUSINESS OPPORTUNITIES

TECH

NOLO

GY T

RANS

FER

CENT

ERS

AND

BUSI

NESS

INCU

BATO

RS

Tech

nolo

gy T

rans

fer

Cent

ers

and

Busi

ness

Incu

bato

rs

101

Center for Advanced Research in Fundamental and Applied Biomedicine CIAB


University of Concepción81.494.400-KSergio Lavanchy, RectorEdmundo Larenas 234, Concepción, Chile


Luis G. Aguayo, Ph.D.Professor(56-41) 220 3380(56-41) 224 [email protected]




CIAB is dedicated to fundamental and applied research in Cell Biology and its relation to Biomedicine and Biotechnology, studying challenging issues such as membrane transport, signaling and control of gene activity in development, cancer, alcoholism, as well as in infectious and degenerative diseases. The Center is developing a strong relationship with health and pharmaceutical industries, as well as with government organizations to improve human health. Its scientists carry out interdisciplinary studies on important cellular functions in normal and diseased cells using leading edge cellular and molecular techniques. Specifically, CIAB is examining several membrane proteins that function as transporters or receptors that receive external signals and translate them into physiological responses. Also studying intracellular regulation, as well as second messengers in normal and diseased stages in addition to the molecular and genetic basis of neurodegenerative diseases. CIAB will put a significant effort into the study of several genes that regulate the expression of some of these proteins. In addition to performing internationally recognized leading edge research, the Center will serve the Chilean community through outcomes such as improved postgraduate education, social benefit to Chileans (i.e., improved education and health), and finding solutions to major biomedical and biotechnological problems of Chile.

Websitewww.ciab-udec.cl

Business Areas


The strength of CIAB resides in basic science research in areas such as gene regulation, membrane transport, neuroscience and pharmaceutical development. The Center is developing new diagnostic methodologies as well as updated therapeutical application. Four areas that are currently being developed:- Production of new diagnostic tools based on biological markers (SNPs).- Research on novel Chilean natural compounds for use in veterinarian and human medicine.- Research on novel and effective applications of anti-oxidants for treatment of degenerative

disorders.- New drug formulations. The Center is developing a core facility to undertake clinical trials.



102

Center for Biochemical Engineering and Biotechnology CIBYB


University of Chile-Juan Asenjo de LeuzeBeauchef 861, Santiago, Chile


Juan Asenjo de LeuzeDirector(56-2) 978 4713(56-2) 699 [email protected]


N°of Employees 27PhD 7Master degree -Bachelor Degree 20


CIBYB is involved in the generation and optimization of proteins for biotechnological applications in particular using the tools of Systems Biology.The objective of the Center is to develop postgraduate research in the disciplines of biochemical engineering and biotechnology by training doctoral students from Chile and abroad to work in advanced research and to graduate professionals with a critical attitude to new developments in this fast moving field.The Center has initiated “state of the art” research in four main areas: the modelling of protein and enzyme synthesis using recombinant strains (E. coli, Bacillus subtilis and yeast) using metabolomics, gene microarray technology and systems biology; the separation, purification and characterization of proteins based upon the fundamental physicochemical properties of proteins to be separated (pI, charge, molecular weight and hydrophobicity); protein engineering using site directed and random mutagenesis and sophisticated computer models, the culture of animal cells for cell therapy and vectors for gene therapy and the use of hybrid expert systems based on heuristic rules, data bases and mathematical correlations for the synthesis and selection of processes (i.e. processes for the separation and purification of proteins).

Websitewww.cibyb.uchile.cl

Business Areas

Products/Services and OperationCIBYB’s main areas are:Use of Recombinant Strains and Cell Culture This area includes topics such as cloning (recombinant DNA techniques) and the synthesis of recombinant proteins, mathematical modelling and the optimization of the synthesis of enzymes and recombinant proteins using microbial cells and animal cells for cell therapy and vectors for gene therapy. Also the analysis of metabolic fluxes in recombinant cells and the comparison with their gene expression is carried out which includes Metabolomics, gene microarrays and systems biology. Separation and Characterization of Proteins. Protein EngineeringThis area includes the physicochemical and electrophoretic characterization of proteins and the use of protein engineering to study the structure-function relationship of enzymes and find new high activity enzymes by site directed and random mutagenesis (or directed evolution). Also it includes areas such the development of new systems and processes for the separation and efficient purification of proteins (new techniques in liquid-liquid extraction and adsorption processes (chromatography) using membranes for ion-exchange and affinity and mathematical modelling) and the optimization of these systems. Process Design using Computational Tools This area includes work on the use of Expert Systems for the optimal selection, synthesis and design of processes. The type of expert system which has been developed is a hybrid system, with wide application in different areas of engineering that allows the use of data bases on the material to be processed and separated (e.g. cell extract with protein product or effluent that needs treatment) with physicochemical and thermodynamic information in addition to heuristic rules and mathematical correlations for design. Also, modern methods of optimization of biotechnology processes in multipurpose and multiproduct plants have been developed. Mathematical and Bioinformatic Methods. Analysis of Genes, use of Microarrays and Systems Biology Computational and bioinformatic studies are an essential help for the investigation of structure-function relationship and elucidation of the 3-D structure of proteins and for Protein Engineering in a similar way to that which the development of mathematical methods and appropriate statistics are essential to correlate cell function and metabolic fluxes with the expression of genes which are carried out with analysis of microarrays. Mathematical Models of Cell metabolism and of Gene Regulation of Metabolic Flows are presently being built


TECH

NOLO

GY T

RANS

FER

CENT

ERS

AND

BUSI

NESS

INCU

BATO

RS

Tech

nolo

gy T

rans

fer

Cent

ers

and

Busi

ness

Incu

bato

rs

103

Center for Clinical Research and Pharmacological Studies CICEF


University of Chile60.910.000 - 1 Pablo CaviedesIndependencia 1027, Santiago, Chile


Pablo Caviedes, MDDirector(56-2) 978 6145(56-2) 735 5855(56-9) 256 [email protected]




CICEF was created in January 2006, focused on clinical and preclinical pharmacological research.It’s composed of several clinical research leaders, with proven expertise in pediatric infectology, vaccinology, preclinical and clinical pharmacology, cardiovascular diseases, obstetrics and neonatology.CICEF specialists have a recognized track record in international multicenter clinical trials, especially in pediatrics. They have successfully coordinated networking collaborations with 25 outpatient clinics, 3 pediatric emergency hospitals, 12 neonatology units, 3 large pediatric hospitals, and 12 pediatric inpatient services in Santiago and provinces. CICEF has access to a large clinical base (more than 1500 hospital beds and more that 500. 000 children between 0 and 18 years of age).The Center is harbored at the University of Chile’s Faculty of Medicine, and its members are faculty professors of the Biomedical Sciences Institute in this Faculty. The platform provides expertise in clinical trials, and strong support from well established basic and preclinical laboratories, all of which constitute an organization of highly recognized leadership.The Center handles clinical trials in Phase II and III, which are carried out in collaboration with a large network of hospitals and outpatient centers localized in the country, following GMP regulations.

Websitewww.cicef.cl

Business Areas


CICEF provides a platform for clinical trials from phase II to IV, both in ambulatory and hospitalized patients, with special expertise in drug and vaccine evaluation.Also the center offers highly qualified professional training and carries out epidemiological studies.CICEF is supported by state of the art infrastructure, and is integrated with a large network of health care facilities (hospitals and outpatient centers).



104

Institute of Biomedical Sciences ICBM


University of Chile60.910.000-1Norbel GalantiCasilla 70086, Santiago7, Chile


Norbel GalantiDirector(56-2) 978 6475(56-2) 735 [email protected]




The ICBM was created in 1997 with the overall aim to promote high quality research and teaching in biomedicine with special emphasis on integration of scientists within the Faculty of Medicine. The Institute thrives for academic excellence and considers that permanent renovation is a key element for its development.The core of the ICBM are 240 Faculty members formerly grouped in several departments distributed throughout the Faculty of Medicine, currently grouped in 79 accredited laboratories (55 fully established and 24 developing) organized within 9 Disciplinary Programs e.g. Physiology and Biophysics, Cellular and Molecular Biology, Molecular and Clinical Pharmacology, Human Genetics, Immunology, Microbiology and Mycology, Anatomy and Developmental Biology, Pathophysiology and Virology. The Institute is responsible for providing insights for the progress of the discipline, training of new Faculty within the field, and assurance of high quality pre and postgraduate teaching.Besides the core of research-academicians the ICBM counts with the support of over 250 technicians with different levels of qualification, and administrators that aid research and teaching activities.

Websitewww.icbm.cl

Business Areas


The ICBM main products are:- Viral isolation- Indirect Immunofluorescency detection of specific antigens- Typification- Immunodiagnosis- Molecular Biology diagnosis


TECH

NOLO

GY T

RANS

FER

CENT

ERS

AND

BUSI

NESS

INCU

BATO

RS

Tech

nolo

gy T

rans

fer

Cent

ers

and

Busi

ness

Incu

bato

rs

105

Núcleo Biotecnología Curauma


Pontifica Universidad Católica de Valparaíso (PUCV)81.669.200-8Alfonso MugaCurauma, Valparaíso, Chile


Sergio MarshallPro Rector for Research and Grad studies(56-32) 227 3444(56-32) 227 3394(56-9) 744 [email protected]


N°of Employees -


The Núcleo de Biotecnología Curauma is an initiative of the Pontificia Universidad Católica de Valparaíso (PUCV), a well established university devoted to develop high quality research, technical assistantship and technology transfer to industries.Biotechnology and Biochemical Engineering fields have been the most important developing areas of this University in the last 30 years, been the first and still the only University in Chile which graduates Biochemical Engineers.The Center will be dedicate to postgraduate research, technology transfer and industrial teaching in three main fields:- Production and use of active biomolecules; including genomics, fermentation and purification.- Production and use of enzymes for productive process soluble and immobilized systems.- Environmental biotechnology; gaseous, liquid and solid wastes treatment.

Websitewww.ucv.cl/vriea

Business Areas


Our research is based in high quality standards and a long tradition in biotechnology and biochemical engineering. Our main services will be:- Active biomolecules production (vaccines, antibiotics, etc)- Production and use of enzymes- Environmental biotechnology and clean production- Merging basic research- Applied research and engineering aspects of process or molecules development.



106

Salvador Hospital Rheumatology Section


University of Chile60.910.000 - 1 University of ChileOscar Neira MD.Av. Salvador 486. Providencia, Santiago.


Oscar Neira MD.Chief, Rheumatology Section(56-2) 340 4633(56-2) 340 4349(56-9) 334 [email protected]


N°of Employees 10


This is a rheumatology clinical research center in a public teaching hospital. Its principal task is out and in-patient care. Also, Rheumatology teaching under and postgraduate. The Center carries out clinical and pharmacological research in rheumatic diseases.

Websitewww.med.uchile.cl/index.html

Business Areas


The Center’s main services include:- Clinical research in rheumatic diseases- Classical internal medicine service- Inpatient and outpatient facilities- Immuno-rheumatology laboratory- Experienced clinical team


Business incubation in Chile is viewed as a support process aimed at accelerating the successful development of companies by providing entrepreneurs with an array of customized resources and services. These services are usually coordinated by the incubator’s management and offered both in the incubator and throughout their network of contacts. Their main goal is to produce successful firms that will grow and leave the program financially viable and freestanding. The “incubator graduates” should have the potential to create jobs, revitalize neighborhoods, and commercialize new technologies while strengthening local and national economies.

Chile has 15 renowned incubators throughout the country, most of them financed by CORFO.

Business Incubators

TECH

NOLO

GY T

RANS

FER

CENT

ERS

AND

BUSI

NESS

INCU

BATO

RS

Tech

nolo

gy T

rans

fer

Cent

ers

and

Busi

ness

Incu

bato

rs


Access Nova AsoIncuba Austral Incuba Genera UC Idea-Incuba Incuba2 Incubatec IncubaUnap Iner Los Lagos Innovo – Usach Octantis Sabio Santiago Innova TarapacaIncuba VentanaUC

Business Incubators



TECH

NOLO

GY T

RANS

FER

CENT

ERS

AND

BUSI

NESS

INCU

BATO

RS

Tech

nolo

gy T

rans

fer

Cent

ers

and

Busi

ness

Incu

bato

rs

109

Biotech Companies IncubatedPrimary ContactJob TitlePostal AddressTelephone

1Antonio Holgado San MartínDirectorDomeyko 2369, Santiago(56-2) 978 4935

Main Incubation Areas

• Biotechnology

• Education

• Mining

Access Nova


Websitewww.accessnova.cl

• Information Technology:

- Hardware (mechanical,

electrical and biotechnology)

- Software, oriented to

management

Biotech Companies IncubatedPrimary ContactJob TitlePostal Address

Telephone

-César Espíndola ArellanoManagerAnfión Muñoz 870, La SerenaLarrondo 1281, Coquimbo, fono 205904(56- 51) 204 194


• Agro and Food Products

• Biotechnology

• Manufactured Goods

• Turism

• Engineering

• Services

AsoIncubaEmail [email protected]@ucn.cl

Websitewww.asoincuba.cl


1Macarena Sáez K ManagerIndependencia Nº 635, Valdivia (56-63) 293 600


• Forestry

• Agro Food

• Functional Food

Austral IncubaEmail [email protected]

Websitewww.australincuba.cl

• Energy

• Biotechnology

• Companies that include

radical innovation in their

respective areas.



110


Telephone

2Maria Soledad Fernández AllendeGeneral ManagerVicuña Mackenna #4860, MaculTower C DICTUC, 3rd floor,. Sgo.56-2 3545458

Main Incubation Areas• Information Technologies (Napsis, Average Yx,

Edunova, MedUC and Chile experience)• Equipment and Machinery Development (Audox,

ProIntech, Dream line)• Bioprocess and Environmental Engineering

(Kross and Rubklean)

Genera UCEmail [email protected]

Websitewww.generauc.cl

• Electrical and Mechanical Engineering (Aislaforte, Special Cages of Faraday, GepUC, Vehicle and Cars of Drag)

• Biotechnology (Center of Aromas, Diagnotec, Beat Drink and Lucien Biotechnology)


Telephone

-Alejandro Silva CarvachoManagerAv. Angamos 601 – AntofagastaAvda. Central Sur 1999, Villa Ayquina - Calama(56- 55) 242 896 – 243 253


• Information Technologies

Incuba 2


2Marcelo Vergara SotoExecutive DirectorEdmundo Larena 234 - Concepción - Chile (56-41) 220 7060


Idea IncubaEmail [email protected]

Websitewww.ideaincuba.cl


Websitewww.incuba2.cl

Main numbers:• 40 initiatives in different stages• 20 in advanced conditions• 10 companies resident in

modules of 20 m2 each.

Main areas:• Biotechnology.• Electronics, Computer science and

Communications.

• Fine Chemistry and the production and processing of new materials.

• Agroindustrial companies• Manufacturing companies


TECH

NOLO

GY T

RANS

FER

CENT

ERS

AND

BUSI

NESS

INCU

BATO

RS

Tech

nolo

gy T

rans

fer

Cent

ers

and

Busi

ness

Incu

bato

rs

111


1Carlos IsaacsExecutive DirectorAv. Francisco Salazar 01145, Temuco (56-45) 325 200


• Forestry• Agroindustry

• Tourism • Quality


Incubatec


Websitewww.incubatec.cl


-Marco Hernández GerenteArturo Prat 2120 1st floor, Iquique(56-57) 394 167


• Turism• Mining

• Aquaculture• Manufactured Goods

• Exporting companies • Information technologies

IncubaUnapEmail [email protected]

Websitewww.incubaunap.cl


Telephone

3María José García General ManagerEdificio Biblioteca 3rd floor, Campus Chinquihue, Puerto Montt. (56-65) 322 384


• Forestry• Farming

• Tourism• Aquaculture

• Fishing• Production of goods

Iner Los LagosEmail [email protected]

Websitewww.inerloslagos.cl



112


2María Teresa Santander GanaDirectorAlameda 2229, Santiago (56-2) 718 4700


• Engineering• Agro and Food Products• Forestry

Innovo - Usach


Websitewww.innovo.cl

• Manufactured Goods• Biotechnology

• Information Technology• Retail

Biotech Companies Incubated

Primary ContactJob TitlePostal AddressTelephone

3 Biotechnology companies1 biomedicine companyAlejandro ValenciaGeneral ManagerSan Antonio 220. Oficina 301.(56-2) 585 4514


• Forestry • Agroindustry • Cattle industry • Biotechnological

SABIOEmail [email protected]

Websitehttp://www.sabio.cl

Biotech Companies Incubated

Primary ContactJob TitlePostal AddressTelephone

9 Biotechnology companies1 biomedicine companyGabriel HidalgoGeneral ManagerAv. Presidente Errázuriz 3485, Las Condes(56-2) 369 3531

OctantisEmail [email protected]

Websitewww.octantis.cl


Octantis’ numbers since 2003:• 2.600 business profiles/ideas

pipeline• 80 accepted Projects• 42 new start-ups• Over US$ 8 million projected

revenues for 2006 in top 10 Octantis companies.

Main areas:• Biomedicine• Agro and Food• Biotechnology• Aquaculture • Environmental

• 12 international patents in process• Over US$ 800 thousand in grants

and seed capital• Over US$ 1,2 million of angel

investing in our portfolio


TECH

NOLO

GY T

RANS

FER

CENT

ERS

AND

BUSI

NESS

INCU

BATO

RS

Tech

nolo

gy T

rans

fer

Cent

ers

and

Busi

ness

Incu

bato

rs

113


-Alvaro BustosExecutive DirectorVictoria Nº 456, Santiago (56-2) 554 5494

Main Incubation Areas Main areas:

• Commercialization• Electronic devises

Santiago Innova


Websitewww.santiagoinnova.cl

• Industrial engineering • Manufactured goods


-Oscar Cofré Espinoza ManagerAV. General Velásquez Nº 1775 (56-58) 205 674


• Agroindustry • Manufactured goods

• Turism • Mining

• Information technologies • Aquaculture

TarapacaIncubaEmail [email protected]

Websitewww.tarapacaincuba.cl


-Alexis Camhi General ManagerAv. El Parque 4161 of. 303 - Ciudad Empresarial - Huechuraba -Santiago (56-2) 580 6400


• Agro and Food Products• Environmental solutions


• Education• Real-estate

VentanaUCEmail [email protected]

Websitewww.ventanauc.com

• 120 companies have received support from Santiago Innova



INCE

NTIV

ES F

OR IN

VEST

ORS

Ince

ntiv

es fo

r In

vest

ors

115

Incentives for Investors



CORFO launched the High Technology Investment Program in 2000 with the purpose of attracting technology-intensive foreign investment and assisting companies interested in establishing permanent operations in Chile.

The Program encourages foreign investment by offering a range of services to help companies set up successful ventures in Chile.

To date, CORFO has assisted over 50 companies to establish offshore operations in Chile. These companies range from businesses offering international services (contact centers and shared service centers) to enterprises working on the development of cutting edge technology.

Among these service are

Extensive information on Chile Intermediary in related services Financial incentives (reserved for foreign investors)

CORFO’s High TechnologyInvestment Program

INCE

NTIV

ES F

OR IN

VEST

ORS

Ince

ntiv

es fo

r In

vest

ors

CORFO encourages foreign investment and offers a wide range of tools to help companies successfully establish operations in Chile.

How we can help you

Arranging meetings with other business executives and industry leaders in Chile and abroad.

Arranging meetings with equipment suppliers and professional service providers such as lawyers, real estate companies, accountants, relocation specialists, and recruitment centers.

Arranging visits to already installed companies.

Connecting you to local senior and central government officials.

Providing information about Chile and answer other specific enquiries.

Organizing contact meetings.

Supporting your project through investment incentives.

Assisting you to locate suitable venues for your business in Chile.

Our services include:

Any information provided by your organization regarding business proposals and plans related to potential investments in Chile is strictly confidential.

Confidentiality

PARTNERING BUSINESS OPPORTUNITIES /117

Whether your investment project is located in Santiago or elsewhere in Chile, you can apply for financial incentives to support project development.

To be eligible for financial incentives, a project must fulfill at least the following criteria:

The project must be proposed by a foreign company or institution

The project must involve research activities and technological development, adding value to the economy. Projects must consider minimum investment of US$500,000

Applications must be made before the project location is decided.

The application process can be explained in 4 basic steps:

Elegibility:

To determine

if the project

fulfills the

application

criteria.

Application:

Includes project

description and

the applicant

company’s

background.

Assesment:

Financial and

technological

evaluation of

the project

conducted by

CORFO.

Project

Submission

CORFO’s

allocating board

decides whether

or not to support

the project.



Applying for Financial Incentives

Incentives* Financial Support Maximum

Inve

stm

ent P

hase

P

re-in

vest

men

t Pha

se

Pre-investment Studies or

Prospecting Trips to Chile

(HT1)

Project launch Assistance

(HT2)

On-the-job Training(HT3)

Equipment and Infrastructure

(HT4)

Long Term PropertyLeasing(HT5)

Specialized Training &

Recruitment

Feasibility studiesfor you investment

project

The execution of a working plan to assist in project implementation

New employee training program

Acquisition oftechnologicalinfrastructure

and equipment

Long-term lease ofproperty associated with the investment

project

Acquirement of specific knowledgeor recruitment of

experts

Up to 60% of the pre-investment

study cost Max= $30,000 USD

Up to $30,000 USD for start-up activities

Up to 50% of annual salaries

Max= $25,000 USD per person

Up to 40% of the totalinvestment infixed assets

Max= $2,000,000 USD

Up to 40% of total lease amount during the first five years.

Max= $500,000 USD

Up to 50% of specialized training

or recruitment.Max= $100,000 USD

* All incentives are rendered in the form of refunds

INCE

NTIV

ES F

OR IN

VEST

ORS

Ince

ntiv

es fo

r In

vest

ors


CORFO’s Financial Investment Incentives



CORFO funds joint activities of technological centers and businesses in areas of strategic impact and public interest. It enables Chilean companies to innovate, both in products and processes; to use top quality technological equipment and gather the world’s most advanced information through research abroad and the hiring of international experts.

Furthermore, CORFO promotes the start up of new ventures providing grants to seed capital projects and business incubators.

CORFO’s main Innovation Incentives are:

Innovation Incentives

Entrepreneurial Innovation

Technology Transfer

PrecompetitiveInnovation

Entrepreneurship

Private profit oriented R&D on process/product

development

Technology diffusion and transfer from

abroad

Innovations with no clear private ownership or marketable

private rights

Foster entrepreneurship and new ventures

4 funding lines from US$55,000 to US$6,000,000

•Technology missions;

•Internships;•International

consulting;•Patenting;•Technology

Transfer Centers•Funding from

US$30,000 to US$600,000

•Public interest innovation;

•Precompetitive innovation;

•Regional capacity building;

•Funding from US$25,000 to US$1,000,000

•Seed capital;•Incubators;•Network of

angel capitalist;•Funding from

US$12,000 to US$600,000

HEAD OFFICECORFO’s Investment and Development Division

Moneda 921, suite 618Santiago, Chile

Phone: (56-2) 631-8667; 631-8618 and 631-8699Mail: [email protected]; www.corfo.cl/biotechnology

INVESTMENT REPRESENTATIVES ABROAD

UNITED STATES

East Coast One Broadway, 14th Floor Cambridge, MA 02142

Phone: 1-866-240 5673 / 1-617-395 [email protected]

West CoastPhone: 1-310-801 01 49

[email protected]

CANADA100 Boteler Street, Suite 403 Ottawa ONK1N 8Y1

Phone: 1-613-697 [email protected]

SPAINBalmes 421 - 6º A; CP 08022, Barcelona

Phone: 00- 34 93 418 [email protected]

ITALYPiazza Capranica 95 00186 Rome

Phone: 39 [email protected]

FINLAND, SWEDEN, DENMARK & NORWAYNorra Vallgatan 20, 4th floorSE-211 25 Malmoe / Sweden

Mobile: 46 73 99 82 [email protected]

CONTACT US:

mailto:[email protected]

http://www.hightechchile.com/

2007...partnering business opportunities / latin america’s most competitive, peaceful, and stable...

Documents